<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004715" GROUP_ID="ORAL" ID="286204012612314190" MERGED_FROM="" MODIFIED="2010-09-07 13:48:57 +0200" MODIFIED_BY="Luisa Fernandez Mauleffinch" REVIEW_NO="0052" REVMAN_SUB_VERSION="5.0.24" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2010-09-06 17:22:44 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2009-11-23 14:59:10 +0000" MODIFIED_BY="[Empty name]">Pharmacological interventions for pain in patients with temporomandibular disorders</TITLE>
<CONTACT>
<PERSON ID="15528" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Tatiana</FIRST_NAME>
<MIDDLE_INITIALS>V</MIDDLE_INITIALS>
<LAST_NAME>Macfarlane</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Lecturer in Medical Statistics</POSITION>
<EMAIL_1>Tatiana.Macfarlane@abdn.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>School of Medicine and Dentistry</DEPARTMENT>
<ORGANISATION>University of Aberdeen</ORGANISATION>
<ADDRESS_1>Polwarth Building</ADDRESS_1>
<ADDRESS_2>Foresterhill</ADDRESS_2>
<CITY>Aberdeen</CITY>
<ZIP>AB25 2ZD</ZIP>
<REGION>Scotland</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>(+44) (0)1224 551585</PHONE_1>
<PHONE_2/>
<FAX_1>(+44) (0)1224 554761</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2010-09-06 12:48:28 +0100" MODIFIED_BY="Luisa Fernandez Mauleffinch">
<PERSON ID="27425756972171894742091123153125" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Helen</FIRST_NAME>
<MIDDLE_INITIALS>R</MIDDLE_INITIALS>
<LAST_NAME>Mujakperuo</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>h.mujakperuo.07@aberdeen.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>School of Medicine and Dentistry</DEPARTMENT>
<ORGANISATION>University of Aberdeen</ORGANISATION>
<ADDRESS_1>Polwarth Building, Foresterhill</ADDRESS_1>
<ADDRESS_2/>
<CITY>Aberdeen</CITY>
<ZIP>AB25 2ZD</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="15015" ROLE="AUTHOR">
<PREFIX>Mrs</PREFIX>
<FIRST_NAME>Margaret</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Watson</LAST_NAME>
<SUFFIX/>
<POSITION>Research and Development Training Fellow</POSITION>
<EMAIL_1>m.c.watson@abdn.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of General Practice and Primary Care</DEPARTMENT>
<ORGANISATION>University of Aberdeen</ORGANISATION>
<ADDRESS_1>Westburn Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Aberdeen</CITY>
<ZIP>AB25 2AY</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 1224 553785</PHONE_1>
<PHONE_2/>
<FAX_1>+44 1224 840683</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="35943457739794196319091123152429" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Roderick</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Morrison</LAST_NAME>
<SUFFIX/>
<POSITION>Consultant Oral and Maxillofacial Surgeon</POSITION>
<EMAIL_1>rmorrison3@nhs.net</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Grampian Regional Maxillofacial Unit</DEPARTMENT>
<ORGANISATION>Aberdeen Royal Infirmary</ORGANISATION>
<ADDRESS_1>Foresterhill</ADDRESS_1>
<ADDRESS_2/>
<CITY>Aberdeen</CITY>
<ZIP>AB25 2ZN</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="15528" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Tatiana</FIRST_NAME>
<MIDDLE_INITIALS>V</MIDDLE_INITIALS>
<LAST_NAME>Macfarlane</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Lecturer in Medical Statistics</POSITION>
<EMAIL_1>Tatiana.Macfarlane@abdn.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>School of Medicine and Dentistry</DEPARTMENT>
<ORGANISATION>University of Aberdeen</ORGANISATION>
<ADDRESS_1>Polwarth Building</ADDRESS_1>
<ADDRESS_2>Foresterhill</ADDRESS_2>
<CITY>Aberdeen</CITY>
<ZIP>AB25 2ZD</ZIP>
<REGION>Scotland</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>(+44) (0)1224 551585</PHONE_1>
<PHONE_2/>
<FAX_1>(+44) (0)1224 554761</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2010-09-06 17:22:44 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="6" MONTH="9" YEAR="2010"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="2" MONTH="8" YEAR="2010"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="5" MONTH="10" YEAR="2012"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2004"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2004"/>
</DATES>
<WHATS_NEW/>
<HISTORY/>
<SOURCES_OF_SUPPORT MODIFIED="2009-11-23 11:51:19 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2009-11-23 11:51:19 +0000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2009-11-23 11:51:19 +0000" MODIFIED_BY="[Empty name]">
<NAME>University of Aberdeen MSc Programme in Clinical Pharmacology</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-09-07 12:27:50 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2010-09-06 17:31:12 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2009-11-14 22:44:29 +0000" MODIFIED_BY="[Empty name]">Pharmacological interventions for pain in patients with temporomandibular disorders</TITLE>
<SUMMARY_BODY MODIFIED="2010-09-06 17:31:12 +0100" MODIFIED_BY="[Empty name]">
<P>Temporomandibular disorders (TMD) are disorders that affect the joint between the temporal bone on the side of the head and the mandibular (jaw) bone of the face, and the associated muscles. Pain is the defining feature of TMD and the primary reason for seeking care. TMD may also involve joint noises or restricted jaw function or both. Different medicines are used to treat pain due to temporomandibular disorders (TMD). These include simple painkillers (analgesics) and medicines which reduce inflammation and treat pain (for example, non-steroidal anti-inflammatory drugs, corticosteroids). Medicines (called benzodiazepines) are sometimes used to reduce tension and spasm in the muscles affected by TMD. In addition, some antidepressant medicines (called tricyclic antidepressants) are used in low doses to help patients with TMD and are thought to be effective because they reduce muscle tension in patients who grind their teeth. This review found that there was not enough evidence to decide which medicines are effective in reducing pain due to chronic TMD.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2010-09-06 17:32:17 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2009-11-14 22:41:45 +0000" MODIFIED_BY="[Empty name]">
<P>Temporomandibular disorders (TMD) are a group of disorders affecting the temporomandibular joints and the muscles of mastication. TMDs are treated with a wide range of drugs. The extent to which the use of these drugs is based upon evidence is unknown.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2010-09-06 17:32:17 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the effectiveness of pharmacological interventions both alone and in combination with non-pharmacological therapy in relieving pain in patients with chronic TMD.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2010-09-06 17:29:23 +0100" MODIFIED_BY="[Empty name]">
<P>Electronic searches of the Cochrane Oral Health Group's Trials Register (2 August 2010), CENTRAL (<I>The Cochrane Library</I> 2010, Issue 3), MEDLINE via OVID<I> </I>(1950 to 2 August 2010), EMBASE via OVID<I> </I>(1980 to 2 August 2010) and CINAHL via EBSCO<I> </I>(1981 to 2 August 2010) were conducted. Reference lists of articles and previous reviews were scanned for relevant articles and authors were contacted for further information where appropriate.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-11-14 22:42:42 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) in which a pharmacological agent was compared with placebo for the management of pain in patients with TMD. Parenteral routes of administration were excluded.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2010-09-06 17:29:47 +0100" MODIFIED_BY="[Empty name]">
<P>Duplicate data extraction and assessment of risk of bias in included studies was performed.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2010-08-16 16:15:07 +0100" MODIFIED_BY="[Empty name]">
<P>Eleven studies were included with a total of 496 participants. The primary outcome of most of the studies was pain. The risk of bias in the included studies was variable. Whilst four studies showed significant pain relief for the active treatment, three were of poor quality. Most adverse effects were mild to moderate in severity. Four studies reported withdrawals due to severe adverse reactions, but insufficient information was provided regarding the trial groups from which the withdrawals occurred. No meta-analysis was conducted due to lack of similarities across the included studies.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2010-08-16 11:55:05 +0100" MODIFIED_BY="[Empty name]">
<P>There is insufficient evidence to support or not support the effectiveness of the reported drugs for the management of pain due to TMD. There is a need for high quality RCTs to derive evidence of the effectiveness of pharmacological interventions to treat pain associated with TMD.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2010-09-07 12:27:50 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2010-09-07 10:18:46 +0100" MODIFIED_BY="[Empty name]">
<P>Temporomandibular disorder (TMD) is a clinical term which is used to describe the musculoskeletal disorders affecting the temporomandibular joints (TMJs) and their associated musculature (<LINK REF="REF-Okeson-1997" TYPE="REFERENCE">Okeson 1997</LINK>). It is a collective term which represents a diverse group of pathologies involving the temporomandibular joint, the muscles of mastication, or both (<LINK REF="REF-Manfredini-et-al-2006" TYPE="REFERENCE">Manfredini et al 2006</LINK>). Pain is the defining feature in TMD and the primary reason for seeking care. TMD also may involve joint noises and/or restricted jaw function (<LINK REF="REF-Dimitroulis-1998" TYPE="REFERENCE">Dimitroulis 1998</LINK>). Although most patients cope well with symptoms, there are some patients in whom the disease is chronic, i.e. longer than 3 months duration. As with many musculoskeletal conditions, the ability to cope with pain and other symptoms varies between individuals and there may be episodes of acute exacerbation of chronic TMD. Patients who are referred to maxillofacial services and still have symptoms at the first appointment will on the whole have had TMD symptoms for 3 months or more and by our definition would therefore be chronic. It is difficult to comment about TMD that resolves within 3 months as these cases seldom present in secondary clinical setting. Non-surgical managements include reassurance, patient education, pharmacotherapy, occlusal therapy, physiotherapy, behavioural therapy and psychotherapy. Surgical treatments include arthrocentesis, arthroscopy and arthrotomy (<LINK REF="REF-Dimitroulis-1998" TYPE="REFERENCE">Dimitroulis 1998</LINK>).</P>
<P>The primary intervention for pain in patients with TMD is the use of pharmacotherapy (<LINK REF="REF-Dionne-1997" TYPE="REFERENCE">Dionne 1997</LINK>; <LINK REF="REF-Hersh-et-al-2008" TYPE="REFERENCE">Hersh et al 2008</LINK>). The aim of pharmacotherapy is not curative but rather to aid the patients in managing the dysfunction and discomfort which occurs as the result of suffering from such a chronic disorder (<LINK REF="REF-Dionne-1997" TYPE="REFERENCE">Dionne 1997</LINK>). It is also the primary intervention because many of the surgical and dental therapies for TMD are not scientifically proven to be effective (<LINK REF="REF-Hersh-et-al-2008" TYPE="REFERENCE">Hersh et al 2008</LINK>). A wide range of pharmacotherapeutic agents are used for TMD (<LINK REF="REF-Dionne-1997" TYPE="REFERENCE">Dionne 1997</LINK>; <LINK REF="REF-Dimitroulis-1998" TYPE="REFERENCE">Dimitroulis 1998</LINK>; <LINK REF="REF-Borodic-2002" TYPE="REFERENCE">Borodic 2002</LINK>; <LINK REF="REF-Song-et-al-2007" TYPE="REFERENCE">Song et al 2007</LINK>; <LINK REF="REF-Hersh-et-al-2008" TYPE="REFERENCE">Hersh et al 2008</LINK>). However, there is insufficient evidence whether these agents provide any benefit over placebo (<LINK REF="REF-Dionne-1997" TYPE="REFERENCE">Dionne 1997</LINK>).</P>
<P>A number of studies have assessed the effectiveness of pharmacotherapy in the management of this condition (<LINK REF="STD-Rossi-et-al-1983" TYPE="STUDY">Rossi et al 1983</LINK>; <LINK REF="STD-Roldan-et-al-1990" TYPE="STUDY">Roldan et al 1990</LINK>; <LINK REF="STD-Harkins-et-al-1991" TYPE="STUDY">Harkins et al 1991</LINK>; <LINK REF="STD-Ekberg-et-al-1996" TYPE="STUDY">Ekberg et al 1996</LINK>; <LINK REF="STD-Winocur-et-al-2000" TYPE="STUDY">Winocur et al 2000</LINK>; <LINK REF="STD-Nguyen-et-al-2001" TYPE="STUDY">Nguyen et al 2001</LINK>; <LINK REF="STD-Herman-et-al-2002" TYPE="STUDY">Herman et al 2002</LINK>; <LINK REF="STD-Lobo-et-al-2004" TYPE="STUDY">Lobo et al 2004</LINK>; <LINK REF="STD-Ta-and-Dionne-2004" TYPE="STUDY">Ta and Dionne 2004</LINK>; <LINK REF="STD-Kimos-et-al-2007" TYPE="STUDY">Kimos et al 2007</LINK>).</P>
<P>This review is needed to derive robust evidence of the effectiveness of pharmacological treatments for TMD and thus enable practitioners to optimise their treatment of their patients with this condition.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2010-09-06 17:32:35 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the effectiveness of pharmacological interventions both alone and in combination with non-pharmacological therapy in relieving pain in patients with chronic temporomandibular disorders.</P>
</OBJECTIVES>
<METHODS MODIFIED="2010-09-07 10:32:50 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2010-09-07 10:20:42 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2010-09-07 10:19:21 +0100" MODIFIED_BY="[Empty name]">
<P>All randomised controlled trials in which a pharmacological agent was compared with a placebo for the management of pain in patients with temporomandibular disorders. Quasi-randomised trials were excluded.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2010-09-07 10:20:35 +0100" MODIFIED_BY="[Empty name]">
<P>Adult patients aged 18 years and over, who had been clinically or radiographically diagnosed to have TMD irrespective of race, gender, profession or residential location. Trials that included patients without pain both with radiographic evidence of temporomandibular joint (TMJ) pathology and with deviation and/or clicking in the temporomandibular area or muscles of mastication were excluded. TMD diagnostic criteria were specified as follows (<LINK REF="REF-McNeill-1997" TYPE="REFERENCE">McNeill 1997</LINK>).</P>
<P>1. Pain in muscles of mastication, the periauricular area and/or the TMJ that is usually aggravated by manipulation or function.</P>
<P>2. Asymmetric mandibular movement with or without clicking.</P>
<P>3. Limited range of mandibular movement.</P>
<P>4. All patients should have had moderate to severe pain of minimum 3 months duration at the time of entering the trial.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2010-09-07 10:20:42 +0100" MODIFIED_BY="[Empty name]">
<P>The treatment group received a pharmacological agent either alone or in combination with other treatments for TMD. The control group received placebo either alone or in combination with other treatments for TMD. All routes of administration were included except parenteral treatments because other Cochrane systematic reviews had evaluated the parenteral route of administration for the management of TMD (<LINK REF="REF-Shi-et-al-2003" TYPE="REFERENCE">Shi et al 2003</LINK>; <LINK REF="REF-Guo-et-al-2009" TYPE="REFERENCE">Guo et al 2009</LINK>).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2010-06-25 11:23:10 +0100" MODIFIED_BY="[Empty name]">
<P>The outcome measures that were analysed in this review were divided into three main groups.</P>
<P>1. Patient-reported pain relief which was assessed on the visual analogue scale (VAS) or some other categorical scale which had been validated.</P>
<P>2. Patient global assessment of improvement, time to symptom relief, duration of symptom relief, overall quality of life and analgesic use were also evaluated.</P>
<P>3. All adverse events which occurred during the trial. This analysis took into account the types of adverse events, the number of participants affected, the number of events and any withdrawals from the trial which took place as a result of the intervention.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2010-09-07 10:27:35 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2010-09-07 10:26:35 +0100" MODIFIED_BY="[Empty name]">
<P>The following databases were searched using a search strategy originally developed for MEDLINE. The search strategy combined the subject search with the Cochrane Highly Sensitive Search Strategy for identifying reports of randomised controlled trials (as published in Box 6.4.c in the <I>Cochrane Handbook for</I> <I>Systematic Reviews of Interventions</I> version 5.0.2 updated September 2009) (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>). Reference lists of studies were manually checked to identify any relevant studies. The searches were not restricted by language:</P>
<UL>
<LI>Cochrane Oral Health Group's Trials Register (whole database, 2 August 2010) (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>)</LI>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2010, Issue 3) (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>)</LI>
<LI>MEDLINE via OVID (1950 to 2 August 2010) (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>)</LI>
<LI>EMBASE via OVID (1980 to 2 August 2010) (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>)</LI>
<LI>CINAHL via EBSCO (1981 to 2 August 2010) (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>).</LI>
</UL>
<P/>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2010-09-07 10:27:35 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Handsearching</HEADING>
<P>The following journals were handsearched:</P>
<UL>
<LI>
<I>Pain</I> (1975 to 2009)</LI>
<LI>
<I>Cranio: the Journal of Craniomandibular Practice</I> (1995 to 2009)</LI>
<LI>
<I>Journal of Craniomandibular Disorders</I> (1987 to 1992).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Correspondence</HEADING>
<P>Members of the Oral Facial Pain Interest Group of the International Association for the Study of Pain were contacted via e-mail to enquire if they had knowledge of any unpublished materials that were relevant to this review. The authors of included studies were also contacted for the same purpose. The authors of studies which were considered for inclusion in this review but did not report all the necessary information were also contacted for clarification.</P>
</SUBSECTION>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2010-09-07 10:32:50 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2010-09-07 10:27:52 +0100" MODIFIED_BY="[Empty name]">
<P>The titles and abstracts of all studies identified by the electronic searches were scanned independently by the review authors (Helen Mujakperuo (HM) and Tatiana Macfarlane (TM)/Margaret Watson (MW)). Full articles were obtained for studies which appeared to meet the inclusion criteria for further assessment. All disagreements about study inclusion were resolved by discussion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2010-09-07 10:27:58 +0100" MODIFIED_BY="[Empty name]">
<P>Duplicate data extraction was conducted for all included studies (HM and TM/MW) using a data extraction form. Data which were extracted included information on the characteristics of the trial participants, the type of interventions, and the different outcome measures that were used in those trials. Other information collected included the duration of the individual trials as well as any interim assessments that were conducted during the trial. All disagreements about data extraction were resolved by discussion.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2010-09-07 10:31:41 +0100" MODIFIED_BY="[Empty name]">
<P>The risk of bias assessment tool was used as described by <LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>. This includes judgement of whether sequence generation was adequate, if there was evidence of allocation concealment, blinding and incomplete outcome data had been addressed. We also examined study publications for any evidence of selective reporting of outcomes or any other issues that may bias the results as described in Table 8.5.c of the <I>Cochrane Handbook for</I> <I>Systematic Reviews of Interventions</I> version 5.0.2 (updated September 2009) (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>). The results of the assessment are summarised in a risk of bias summary and risk of bias graph. Sample size calculation and pharmaceutical industry sponsorship were also noted.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2010-06-26 13:07:23 +0100" MODIFIED_BY="[Empty name]">
<P>The effect measures used for analysing dichotomous data were the risk ratio (RR) and 95% confidence interval (CI). For these calculations, an event was defined as when the trial participants indicated that they still had pain or, alternatively, indicated a lack of improvement after the intervention, depending on how it was defined in published papers. A non-event was defined as improvement (i.e. no pain) or cure. The effect measures used for analysing continuous data were the mean difference and the 95% CI, which measured the absolute difference between the mean values in the intervention groups and control groups of the included trials. <LINK REF="REF-Revman5" TYPE="REFERENCE">Revman5</LINK> software was used to calculate the RR, mean difference and 95% CI for all the included studies. Forest plots were also constructed to give a graphical representation of the effects of each intervention on pain in TMD.</P>
</EFFECT_MEASURES>
<HETEROGENEITY_ASSESSMENT MODIFIED="2010-09-07 10:32:07 +0100" MODIFIED_BY="[Empty name]">
<P>Heterogeneity was assessed by reviewing the characteristics of the included studies. If meta-analysis was possible, heterogeneity would be assessed by inspection of a graphical display of the estimated treatment effects from the trials along with their 95% CI, by Cochran&#8217;s Q test and the I<SUP>2</SUP> statistic undertaken before each meta-analysis.</P>
</HETEROGENEITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2010-09-07 10:32:50 +0100" MODIFIED_BY="[Empty name]">
<P>No meta-analysis was conducted due to lack of similarities across the included studies. However, if meta-analysis were possible, a random-effects model would be used provided there were four or more trials included in the meta-analysis, and the data from cross-over trials would be combined with that of similar parallel group trials, using the techniques described by <LINK REF="REF-Elbourne-et-al-2002" TYPE="REFERENCE">Elbourne et al 2002</LINK>. Forest plots were not presented by therapeutic class because the review comprised few included studies and we thought it better to present their results separately. </P>
</DATA_SYNTHESIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2010-09-07 12:27:50 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2010-09-07 10:41:39 +0100" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2010-09-07 10:33:34 +0100" MODIFIED_BY="[Empty name]">
<P>A total of 2285 studies were identified from the electronic searches and handsearching. After the initial screening, 48 studies were identified as potentially relevant. A flow chart showing the process by which the included studies were chosen is presented as <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2010-09-07 10:41:05 +0100" MODIFIED_BY="[Empty name]">
<P>Eleven randomised controlled trials (RCTs) fulfilled the inclusion criteria (<LINK REF="STD-Rossi-et-al-1983" TYPE="STUDY">Rossi et al 1983</LINK>; <LINK REF="STD-Roldan-et-al-1990" TYPE="STUDY">Roldan et al 1990</LINK>; <LINK REF="STD-Harkins-et-al-1991" TYPE="STUDY">Harkins et al 1991</LINK>; <LINK REF="STD-Ekberg-et-al-1996" TYPE="STUDY">Ekberg et al 1996</LINK>; <LINK REF="STD-Winocur-et-al-2000" TYPE="STUDY">Winocur et al 2000</LINK>; <LINK REF="STD-Nguyen-et-al-2001" TYPE="STUDY">Nguyen et al 2001</LINK>; <LINK REF="STD-Herman-et-al-2002" TYPE="STUDY">Herman et al 2002</LINK>; <LINK REF="STD-Lobo-et-al-2004" TYPE="STUDY">Lobo et al 2004</LINK>; <LINK REF="STD-Ta-and-Dionne-2004" TYPE="STUDY">Ta and Dionne 2004</LINK>; <LINK REF="STD-Kimos-et-al-2007" TYPE="STUDY">Kimos et al 2007</LINK>; <LINK REF="STD-Tchivileva-et-al-2010" TYPE="STUDY">Tchivileva et al 2010</LINK>) and involved a total of 496 participants. Six studies were conducted in the USA (<LINK REF="STD-Harkins-et-al-1991" TYPE="STUDY">Harkins et al 1991</LINK>; <LINK REF="STD-Nguyen-et-al-2001" TYPE="STUDY">Nguyen et al 2001</LINK>; <LINK REF="STD-Herman-et-al-2002" TYPE="STUDY">Herman et al 2002</LINK>; <LINK REF="STD-Lobo-et-al-2004" TYPE="STUDY">Lobo et al 2004</LINK>; <LINK REF="STD-Ta-and-Dionne-2004" TYPE="STUDY">Ta and Dionne 2004</LINK>; <LINK REF="STD-Tchivileva-et-al-2010" TYPE="STUDY">Tchivileva et al 2010</LINK>), and one each in Canada (<LINK REF="STD-Kimos-et-al-2007" TYPE="STUDY">Kimos et al 2007</LINK>), Sweden (<LINK REF="STD-Ekberg-et-al-1996" TYPE="STUDY">Ekberg et al 1996</LINK>), Israel (<LINK REF="STD-Winocur-et-al-2000" TYPE="STUDY">Winocur et al 2000</LINK>), Argentina (<LINK REF="STD-Roldan-et-al-1990" TYPE="STUDY">Roldan et al 1990</LINK>) and Chile (<LINK REF="STD-Rossi-et-al-1983" TYPE="STUDY">Rossi et al 1983</LINK>). Most participants were female (n = 414, 83%). The smallest study had 20 participants (<LINK REF="STD-Harkins-et-al-1991" TYPE="STUDY">Harkins et al 1991</LINK>) and the largest had 83 participants (<LINK REF="STD-Rossi-et-al-1983" TYPE="STUDY">Rossi et al 1983</LINK>). The included studies were published between 1983 and 2010, with seven studies published after 2000. Thirteen comparisons were made which were divided into five groups based on therapeutic class of the drugs.</P>
<P>(1) Non-steroidal anti-inflammatory drugs (NSAIDs), salicylate and cyclo-oxygenase 2 (COX-2) inhibitors versus placebo.<BR/>- Oral piroxicam versus placebo (<LINK REF="STD-Roldan-et-al-1990" TYPE="STUDY">Roldan et al 1990</LINK>).<BR/>- Oral diclofenac sodium versus placebo (<LINK REF="STD-Ekberg-et-al-1996" TYPE="STUDY">Ekberg et al 1996</LINK>).<BR/>- Oral naproxen versus placebo (<LINK REF="STD-Ta-and-Dionne-2004" TYPE="STUDY">Ta and Dionne 2004</LINK>).<BR/>- Topical methyl salicylate versus placebo (<LINK REF="STD-Lobo-et-al-2004" TYPE="STUDY">Lobo et al 2004</LINK>).<BR/>- Oral celecoxib versus placebo (<LINK REF="STD-Ta-and-Dionne-2004" TYPE="STUDY">Ta and Dionne 2004</LINK>).</P>
<P>(2) Benzodiazepines versus placebo.<BR/>- Oral clonazepam versus placebo (<LINK REF="STD-Harkins-et-al-1991" TYPE="STUDY">Harkins et al 1991</LINK>; <LINK REF="STD-Herman-et-al-2002" TYPE="STUDY">Herman et al 2002</LINK>).<BR/>- Oral prazepam versus placebo (<LINK REF="STD-Rossi-et-al-1983" TYPE="STUDY">Rossi et al 1983</LINK>).<BR/>- Oral diazepam versus placebo (<LINK REF="STD-Roldan-et-al-1990" TYPE="STUDY">Roldan et al 1990</LINK>).</P>
<P>(3) Anticonvulsant versus placebo.<BR/>- Oral gabapentin versus placebo (<LINK REF="STD-Kimos-et-al-2007" TYPE="STUDY">Kimos et al 2007</LINK>).</P>
<P>(4) Muscle relaxant versus placebo.<BR/>- Oral cyclobenzaprine versus placebo (<LINK REF="STD-Herman-et-al-2002" TYPE="STUDY">Herman et al 2002</LINK>).</P>
<P>(5) Miscellaneous drugs versus placebo.<BR/>- Topical capsaicin versus placebo (<LINK REF="STD-Winocur-et-al-2000" TYPE="STUDY">Winocur et al 2000</LINK>).<BR/>- Oral glucosamine hydrochloride/chondroitin sulphate versus placebo (<LINK REF="STD-Nguyen-et-al-2001" TYPE="STUDY">Nguyen et al 2001</LINK>).<BR/>- Oral propranolol versus placebo (<LINK REF="STD-Tchivileva-et-al-2010" TYPE="STUDY">Tchivileva et al 2010</LINK>).</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2010-09-07 10:41:39 +0100" MODIFIED_BY="[Empty name]">
<P>Thirty-seven additional studies were assessed. The reasons for their exclusion are presented in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-09-07 10:48:08 +0100" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> summarize the assessment of the risk of bias. A full description of each study is available in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> tables.</P>
<SUBSECTION>
<HEADING LEVEL="3">Sample size calculation</HEADING>
<P>Only one study (<LINK REF="STD-Tchivileva-et-al-2010" TYPE="STUDY">Tchivileva et al 2010</LINK>) presented a sample size calculation, and other included studies were under-powered to detect any significant difference between the intervention and placebo.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sequence generation</HEADING>
<P>Of the 11 included studies, only six had adequate sequence generation (<LINK REF="STD-Nguyen-et-al-2001" TYPE="STUDY">Nguyen et al 2001</LINK>; <LINK REF="STD-Herman-et-al-2002" TYPE="STUDY">Herman et al 2002</LINK>; <LINK REF="STD-Lobo-et-al-2004" TYPE="STUDY">Lobo et al 2004</LINK>; <LINK REF="STD-Ta-and-Dionne-2004" TYPE="STUDY">Ta and Dionne 2004</LINK>; <LINK REF="STD-Kimos-et-al-2007" TYPE="STUDY">Kimos et al 2007</LINK>; <LINK REF="STD-Tchivileva-et-al-2010" TYPE="STUDY">Tchivileva et al 2010</LINK>). Sequence generation for the rest of the studies was unclear.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Allocation concealment</HEADING>
<P>Five studies achieved adequate allocation concealment (<LINK REF="STD-Nguyen-et-al-2001" TYPE="STUDY">Nguyen et al 2001</LINK>; <LINK REF="STD-Lobo-et-al-2004" TYPE="STUDY">Lobo et al 2004</LINK>; <LINK REF="STD-Ta-and-Dionne-2004" TYPE="STUDY">Ta and Dionne 2004</LINK>; <LINK REF="STD-Kimos-et-al-2007" TYPE="STUDY">Kimos et al 2007</LINK>; <LINK REF="STD-Tchivileva-et-al-2010" TYPE="STUDY">Tchivileva et al 2010</LINK>). Allocation concealment for the rest of the studies was unclear.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Blinding</HEADING>
<P>All of the included studies were double-blinded.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Completeness of outcome data</HEADING>
<P>Six studies addressed incompleteness of outcome data (<LINK REF="STD-Harkins-et-al-1991" TYPE="STUDY">Harkins et al 1991</LINK>; <LINK REF="STD-Ekberg-et-al-1996" TYPE="STUDY">Ekberg et al 1996</LINK>; <LINK REF="STD-Nguyen-et-al-2001" TYPE="STUDY">Nguyen et al 2001</LINK>; <LINK REF="STD-Herman-et-al-2002" TYPE="STUDY">Herman et al 2002</LINK>; <LINK REF="STD-Kimos-et-al-2007" TYPE="STUDY">Kimos et al 2007</LINK>; <LINK REF="STD-Tchivileva-et-al-2010" TYPE="STUDY">Tchivileva et al 2010</LINK>). Only two studies achieved 100% follow-up (<LINK REF="STD-Rossi-et-al-1983" TYPE="STUDY">Rossi et al 1983</LINK>; <LINK REF="STD-Herman-et-al-2002" TYPE="STUDY">Herman et al 2002</LINK>). For the rest of the studies completeness was unclear. Only two studies that reported incomplete follow-up conducted an intention-to-treat analysis (<LINK REF="STD-Kimos-et-al-2007" TYPE="STUDY">Kimos et al 2007</LINK>; <LINK REF="STD-Tchivileva-et-al-2010" TYPE="STUDY">Tchivileva et al 2010</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Selective reporting</HEADING>
<P>All studies were judged to be free of selective reporting.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Other bias</HEADING>
<P>Five of the studies were considered to be free of other bias (<LINK REF="STD-Ekberg-et-al-1996" TYPE="STUDY">Ekberg et al 1996</LINK>; <LINK REF="STD-Winocur-et-al-2000" TYPE="STUDY">Winocur et al 2000</LINK>; <LINK REF="STD-Nguyen-et-al-2001" TYPE="STUDY">Nguyen et al 2001</LINK>; <LINK REF="STD-Ta-and-Dionne-2004" TYPE="STUDY">Ta and Dionne 2004</LINK>; <LINK REF="STD-Tchivileva-et-al-2010" TYPE="STUDY">Tchivileva et al 2010</LINK>) and for two other bias was present (<LINK REF="STD-Harkins-et-al-1991" TYPE="STUDY">Harkins et al 1991</LINK>; <LINK REF="STD-Kimos-et-al-2007" TYPE="STUDY">Kimos et al 2007</LINK>). For the rest of the studies presence of other bias was unclear.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Pharmaceutical industry sponsorship</HEADING>
<P>Four of the included studies were sponsored by the pharmaceutical industry (<LINK REF="STD-Ekberg-et-al-1996" TYPE="STUDY">Ekberg et al 1996</LINK>; <LINK REF="STD-Winocur-et-al-2000" TYPE="STUDY">Winocur et al 2000</LINK>; <LINK REF="STD-Lobo-et-al-2004" TYPE="STUDY">Lobo et al 2004</LINK>; <LINK REF="STD-Kimos-et-al-2007" TYPE="STUDY">Kimos et al 2007</LINK>). In three studies, pharmaceutical industry sponsorship was unclear (<LINK REF="STD-Rossi-et-al-1983" TYPE="STUDY">Rossi et al 1983</LINK>; <LINK REF="STD-Roldan-et-al-1990" TYPE="STUDY">Roldan et al 1990</LINK>; <LINK REF="STD-Harkins-et-al-1991" TYPE="STUDY">Harkins et al 1991</LINK>). One study did not have pharmaceutical industry sponsorship but some authors declared conflict of interest due to involvement in a private genetics company (<LINK REF="STD-Tchivileva-et-al-2010" TYPE="STUDY">Tchivileva et al 2010</LINK>).</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2010-09-07 12:27:50 +0100" MODIFIED_BY="[Empty name]">
<P>Data were analysed using <LINK REF="REF-Revman5" TYPE="REFERENCE">Revman5</LINK>. For uniformity data were analysed and presented by rescaling mean VAS on 0 to 100 mm (<LINK REF="STD-Nguyen-et-al-2001" TYPE="STUDY">Nguyen et al 2001</LINK>; <LINK REF="STD-Ta-and-Dionne-2004" TYPE="STUDY">Ta and Dionne 2004</LINK>; <LINK REF="STD-Tchivileva-et-al-2010" TYPE="STUDY">Tchivileva et al 2010</LINK>) and 0 to 1 scale (<LINK REF="STD-Herman-et-al-2002" TYPE="STUDY">Herman et al 2002</LINK>) to 0 to 10 cm scale. The main results are presented separately by duration of pain. According to the protocol, all participants should have had moderate to severe pain of minimum 3 months duration at the time of entering the trial. However, due to the limited number of studies which could be included in this review, all relevant studies were included but analysed on the basis of pain duration (minimum of 3 months pain duration, variable duration of pain, and unknown duration of pain).</P>
<SUBSECTION>
<HEADING LEVEL="3">Minimum of 3 months pain duration</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Comparison of oral benzodiazepine (clonazepam) versus placebo</HEADING>
<P>
<LINK REF="STD-Harkins-et-al-1991" TYPE="STUDY">Harkins et al 1991</LINK>
<BR/>This was a double-blind trial which was conducted for 60 days. There were a total of 20 participants randomised to either clonazepam or placebo. There was no statistically significant difference between the effect of clonazepam and placebo on pain on palpation of the right masseter muscle (mean difference -1.11; 95% confidence interval (CI) -2.66 to 0.44; P = 0.16) or left masseter muscle (mean difference -0.89; 95% CI -2.46 to 0.68; P = 0.27). There was also no statistically significant difference between clonazepam and placebo in patient assessment of pain in the right temporomandibular joint (TMJ) (mean difference -0.74; 95% CI -3.14 to 1.66; P = 0.55) or left TMJ (mean difference -1.36; 95% CI -3.68 to 0.96; P = 0.25) <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>. </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison of oral anticonvulsant (gabapentin) versus placebo</HEADING>
<P>
<LINK REF="STD-Kimos-et-al-2007" TYPE="STUDY">Kimos et al 2007</LINK>
<BR/>This was a double-blind study which was conducted for 12 weeks. A total of 44 participants were randomised to either gabapentin or placebo. In this study, gabapentin demonstrated a statistically significant effect over placebo in reducing spontaneous pain in the TMJ (mean difference -3.20; 95% CI -4.71 to -1.69; P &lt; 0.001) and the number of tender sites on the muscles of mastication (mean difference -4.56; 95% CI -6.99 to -2.13; P &lt; 0.001). Participant assessment of global function showed no significant difference between the gabapentin and placebo groups (mean difference -1.50; 95% CI -3.10 to 0.10; P = 0.07) <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison of topical capsaicin versus placebo</HEADING>
<P>
<LINK REF="STD-Winocur-et-al-2000" TYPE="STUDY">Winocur et al 2000</LINK>
<BR/>This was a double-blind study which was conducted for 4 weeks. A total of 30 participants were randomised to either topical capsaicin or placebo. There was no statistically significant difference between topical capsaicin and placebo in reducing the pain of TMD (mean difference -0.61; 95% CI -2.45 to 1.23; P = 0.52), maximum pain while on the medication (mean difference -0.91; 95% CI -2.89 to 1.07; P = 0.37), and pain on daily activity (mean difference -1.12; 95% CI -3.12 to 0.88; P = 0.27) <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Variable duration of pain</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Comparison of oral NSAID (diclofenac sodium) versus placebo</HEADING>
<P>
<LINK REF="STD-Ekberg-et-al-1996" TYPE="STUDY">Ekberg et al 1996</LINK>
<BR/>This was a double-blind trial which was conducted for 2 weeks. A total of 32 participants were randomised into two parallel groups of diclofenac sodium or placebo. The participants were assessed 2 weeks after completion of the study. There was no statistically significant difference at follow-up between the diclofenac group and the placebo group in this study in daily pain (risk ratio 0.71; 95% CI 0.49 to 1.04; P = 0.08), severe or very severe symptoms (risk ratio 0.88; 95% CI 0.42 to 1.84; P = 0.72), pain at rest (not improved) (risk ratio 0.89; 95% CI 0.46 to 1.76; P = 0.72) or pain on palpation (risk ratio 0.75; 95% CI 0.34 to 1.67; P = 0.48) <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison of oral NSAID (naproxen) versus placebo, and oral COX-2 inhibitor (celecoxib) versus placebo</HEADING>
<P>
<LINK REF="STD-Ta-and-Dionne-2004" TYPE="STUDY">Ta and Dionne 2004</LINK>
<BR/>This was a double-blind study which was conducted for 6 weeks. A total of 68 participants were randomised into three parallel groups of celecoxib, naproxen or placebo. Naproxen was more effective than placebo in reducing the pain of TMD in this study (mean difference -1.70; 95% CI -2.14 to -1.25; P &lt; 0.001). Oral celecoxib did not demonstrate any statistically significant effect compared with placebo (mean difference 0.03; 95% CI -0.40 to 0.45; P = 0.91) <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>; <LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison of topical methyl salicylate versus placebo</HEADING>
<P>
<LINK REF="STD-Lobo-et-al-2004" TYPE="STUDY">Lobo et al 2004</LINK>
<BR/>This was a double-blind study which was conducted for 15 days. A total of 52 participants were randomised to topical methyl salicylate or placebo. Participants were assessed 5 days after completion of the study. There was evidence from this study to suggest that topical methyl salicylate may be beneficial over placebo with respect to reducing spontaneous TMJ pain (mean difference -0.90; 95% CI -1.35 to -0.45; P &lt; 0.001) and spontaneous masseter muscle pain (mean difference -2.00; 95% CI -2.38 to -1.62; P &lt; 0.001) <LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison of oral benzodiazepine (clonazepam) versus placebo, and oral muscle relaxant (cyclobenzaprine) versus placebo</HEADING>
<P>
<LINK REF="STD-Herman-et-al-2002" TYPE="STUDY">Herman et al 2002</LINK>
<BR/>This was a double-blind study which was conducted for 3 weeks. A total of 41 participants were randomised to clonazepam, cyclobenzaprine or placebo. There was no statistically significant difference between the effect of clonazepam and placebo on jaw pain (mean difference -0.20; 95% CI -1.69 to 1.29; P = 0.79) <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>. Cyclobenzaprine also did not demonstrate any evidence of effect on jaw pain compared with placebo (mean difference -1.30; 95% CI -2.67 to 0.07; P = 0.06) <LINK REF="CMP-008.01" TYPE="ANALYSIS">Analysis 8.1</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison of oral glucosamine hydrochloride/chondroitin sulphate versus placebo</HEADING>
<P>
<LINK REF="STD-Nguyen-et-al-2001" TYPE="STUDY">Nguyen et al 2001</LINK>
<BR/>This was a double-blind study which was conducted for 3 months. A total of 45 participants were randomised to either glucosamine hydrochloride/chondroitin sulphate or placebo. There was no statistically significant difference between oral glucosamine hydrochloride/chondroitin sulphate and placebo in reducing pain intensity (mean difference -0.70; 95% CI -2.16 to 0.76; P = 0.35), total pain (mean difference 1.60; 95% CI -8.29 to 11.49; P = 0.75) and pain on palpation of the TMJ (mean difference -0.30; 95% CI -3.09 to 2.49; P = 0.83) <LINK REF="CMP-009.01" TYPE="ANALYSIS">Analysis 9.1</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Pain duration unknown</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Comparison of oral NSAID (piroxicam) versus placebo, and oral benzodiazepine (diazepam) versus placebo</HEADING>
<P>
<LINK REF="STD-Roldan-et-al-1990" TYPE="STUDY">Roldan et al 1990</LINK>
<BR/>This was a double-blind study which was conducted for 15 days. A total of 41 participants were randomised into three parallel groups of piroxicam, diazepam or placebo. There was no statistically significant difference between piroxicam and placebo in reducing the pain of TMD in this study (risk ratio 0.71; 95% CI 0.29 to 1.76; P = 0.46) <LINK REF="CMP-010.01" TYPE="ANALYSIS">Analysis 10.1</LINK>. Diazepam did not demonstrate a statistically significant effect compared with placebo (risk ratio 0.67; 95% CI 0.27 to 1.66; P = 0.38) <LINK REF="CMP-011.01" TYPE="ANALYSIS">Analysis 11.1</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison of oral benzodiazepine (prazepam) versus placebo</HEADING>
<P>
<LINK REF="STD-Rossi-et-al-1983" TYPE="STUDY">Rossi et al 1983</LINK>
<BR/>This was a double-blind study which was conducted for 8 days. There were 83 participants randomised to 5 mg prazepam, 10 mg prazepam or placebo. There was no statistically significant difference in pain reduction between 5 mg prazepam and placebo on spontaneous TMJ pain (risk ratio 0.79; 95% CI 0.45 to 1.38; P = 0.41); TMJ pain during mastication (risk ratio 0.97; 95% CI 0.61 to 1.54; P = 0.90); and improvement in TMJ pain on external palpation (risk ratio 0.75; 95% CI 0.47 to 1.19; P = 0.22) <LINK REF="CMP-012.01" TYPE="ANALYSIS">Analysis 12.1</LINK>. There was also no statistically significant difference in pain reduction between 10 mg prazepam and placebo on spontaneous TMJ pain (risk ratio 1.23; 95% CI 0.81 to 1.88; P = 0.33); TMJ pain during mastication (risk ratio 1.18; 95% CI 0.79 to 1.77; P = 0.42); and improvement in TMJ pain on external palpation (risk ratio 1.10; 95% CI 0.68 to 1.49; P = 0.98) <LINK REF="CMP-012.02" TYPE="ANALYSIS">Analysis 12.2</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison of oral propranolol versus placebo</HEADING>
<P>
<LINK REF="STD-Tchivileva-et-al-2010" TYPE="STUDY">Tchivileva et al 2010</LINK>
<BR/>This was a double-blind, two-period cross-over study. There were 40 participants randomised into two arms. The first arm started with 1 week of 20 mg of propranolol twice a day, followed by a 1-week washout period, and then a 1-week placebo period. The second arm started with 1 week of placebo, followed by a 1-week washout period, and then a week of 20 mg of propranolol twice a day. While pain duration prior to study commencement was not specified, title and text state that patients with "chronic musculoskeletal pain" were included. Reduction in pain intensity rating (primary outcome) comparing propranolol treatment to placebo treatment did not reach statistical significance (P = 0.104) <LINK REF="CMP-013.01" TYPE="ANALYSIS">Analysis 13.1</LINK>. There was also no statistically significant difference in reduction in pain duration (P = 0.802) between propranolol and placebo <LINK REF="CMP-013.03" TYPE="ANALYSIS">Analysis 13.3</LINK>. However, a significantly greater percentage of patients (67.5% versus 32.5%) experienced reduction in pain intensity rating during the propranolol treatment period than the placebo treatment period (P = 0.014) <LINK REF="CMP-013.02" TYPE="ANALYSIS">Analysis 13.2</LINK>. There was also statistically significant difference in reduction in pain index between the propranolol treatment period and the placebo treatment period (P = 0.02) <LINK REF="CMP-013.04" TYPE="ANALYSIS">Analysis 13.4</LINK>. Pharmacogenetic evaluation of propranolol response based on catechol-O-methyltransferase (COMT) haplotype showed that the number of lipopolysaccharide (LPS) alleles was associated with statistically significant variation in the net change in pain index (P = 0.031), but not in net change in pain intensity rating (P = 0.086). Participants with no LPS alleles showed the greatest response. An intermediate effect was observed in the heterozygotes and no effect was noted in LPS homozygotes.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse effects of interventions</HEADING>
<P>All but one study (<LINK REF="STD-Lobo-et-al-2004" TYPE="STUDY">Lobo et al 2004</LINK>) reported adverse effects. Most of the reported adverse effects were mild and similar to the adverse effects reported in the literature. Four of the studies reported drop outs due to the severity of some of these adverse effects. One participant in the clonazepam group withdrew from the study by <LINK REF="STD-Harkins-et-al-1991" TYPE="STUDY">Harkins et al 1991</LINK> due to severe headache. Four of the participants withdrew from the study by <LINK REF="STD-Kimos-et-al-2007" TYPE="STUDY">Kimos et al 2007</LINK> due to adverse effects, but neither the type of adverse effect nor the trial group was specified. Three participants from the topical capsaicin group withdrew from the study by <LINK REF="STD-Winocur-et-al-2000" TYPE="STUDY">Winocur et al 2000</LINK> due to the severity of the burning sensation and redness. Two allergic reactions and one severe abdominal pain led to three withdrawals from the intervention group in the study by <LINK REF="STD-Nguyen-et-al-2001" TYPE="STUDY">Nguyen et al 2001</LINK>. In the study by <LINK REF="STD-Tchivileva-et-al-2010" TYPE="STUDY">Tchivileva et al 2010</LINK> at least one treatment-emergent adverse event was reported by five participants (12.5%) during the propranolol period (namely nausea, diarrhoea, insomnia, dizziness, and fatigue) and four participants (10%) during the placebo period (namely diarrhoea, gastrointestinal bloating, fatigue, and headache). All adverse events in this study were mild and did not result in discontinuation of the study.</P>
<P>Overall, there were no serious adverse events reported defined as any untoward medical occurrence that resulted in death, was life-threatening, required inpatient hospitalisation or prolongation of existing hospitalisation or resulted in persistent or significant disability/incapacity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Dose of drug</HEADING>
<P>Additional <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> summarises information about the drug doses used in the included trials and relates these to the recommended doses for these drugs, where possible. It is important to note that some of these drugs are not available internationally e.g. prazepam is not available in the United Kingdom. Many of these drugs are being used for indications for which they are unlicensed (e.g. celecoxib), so there is no specific dose for the use of these drugs for the management of TMD. Where available, the dose recommendations for the treatment of neuropathic pain have been used to calculate the percentage of maximum daily dose (MDD) for the medicines used in the studies. However, not all medicines used have an official dosage recommendation for neuropathic pain. </P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2010-09-07 12:22:14 +0100" MODIFIED_BY="[Empty name]">
<P>The objective of this review was to assess the effectiveness of pharmacological interventions for pain in patients with temporomandibular disorders (TMD). However, it is worthy of note that the inclusion of studies of patients with pain from temporomandibular joint and surrounding musculature (muscles of mastication) is hampered by lack of uniformity of terminology and precise definition of temporomandibular joint disorders. The diagnostic criteria used by <LINK REF="REF-McNeill-1997" TYPE="REFERENCE">McNeill 1997</LINK> were used as a framework to include studies in this review. The total number of participants in all of the included studies was 496 of which 83% were female. This reflects the reviews by <LINK REF="REF-Dimitroulis-1998" TYPE="REFERENCE">Dimitroulis 1998</LINK>; <LINK REF="REF-Manfredini-et-al-2006" TYPE="REFERENCE">Manfredini et al 2006</LINK> and <LINK REF="REF-Luther-2007" TYPE="REFERENCE">Luther 2007</LINK> which all state that TMD is more common in women with the population of females seeking treatment for TMD being four times the male population. Four of the 11 included studies demonstrated a significant effect of the intervention drug over placebo (<LINK REF="STD-Lobo-et-al-2004" TYPE="STUDY">Lobo et al 2004</LINK>; <LINK REF="STD-Ta-and-Dionne-2004" TYPE="STUDY">Ta and Dionne 2004</LINK>; <LINK REF="STD-Kimos-et-al-2007" TYPE="STUDY">Kimos et al 2007</LINK>; <LINK REF="STD-Tchivileva-et-al-2010" TYPE="STUDY">Tchivileva et al 2010</LINK>). However, the quality assessment which was conducted by the authors in line with the CONSORT statement (<LINK REF="REF-Moher-et-al-2001" TYPE="REFERENCE">Moher et al 2001</LINK>) showed that the methodological quality of all eleven randomised controlled trials included in this review was variable, with most included studies having low quality. The studies by <LINK REF="STD-Nguyen-et-al-2001" TYPE="STUDY">Nguyen et al 2001</LINK>; <LINK REF="STD-Herman-et-al-2002" TYPE="STUDY">Herman et al 2002</LINK>; <LINK REF="STD-Lobo-et-al-2004" TYPE="STUDY">Lobo et al 2004</LINK>; <LINK REF="STD-Kimos-et-al-2007" TYPE="STUDY">Kimos et al 2007</LINK> and <LINK REF="STD-Tchivileva-et-al-2010" TYPE="STUDY">Tchivileva et al 2010</LINK> were of greater quality, however, they were not fully reported according to the CONSORT statement. All except one (<LINK REF="STD-Tchivileva-et-al-2010" TYPE="STUDY">Tchivileva et al 2010</LINK>) of the included studies were under-powered for their level of significance. Of the four studies with significant results, two were pharmaceutical-industry sponsored (<LINK REF="STD-Lobo-et-al-2004" TYPE="STUDY">Lobo et al 2004</LINK>; <LINK REF="STD-Kimos-et-al-2007" TYPE="STUDY">Kimos et al 2007</LINK>). <LINK REF="STD-Tchivileva-et-al-2010" TYPE="STUDY">Tchivileva et al 2010</LINK> did not have pharmaceutical industry sponsorship but some authors declared conflict of interest due to involvement in a private genetics company.</P>
<P>There was significant heterogeneity among the studies which were included in this review. This was unsurprising as various pharmacological interventions were being analysed. There was also heterogeneity in the outcome measures and the tools which were used to assess them. The visual analogue scale (VAS), numerical graph rating scale (NGRS), McGill pain questionnaire and palpation index were the tools used in the included studies. In addition, the VAS was calibrated differently, ranging from 0 to 1, 0 to 10 cm and 0 to 100 mm across different studies. This caused a problem with the comparison of the effects of drugs across various studies as the magnitude of the effect reported varied with the scale and type of tool used.</P>
<P>Of the 11 included studies, eight reported means and standard deviations. None of these studies stated whether the distribution was normal, but for the purpose of this review it was assumed that the authors had checked the assumptions prior to use of parametric tests. It has also been shown, however, that change between skewed baseline and post-treatment data tends towards a normal distribution (<LINK REF="REF-Vickers-2005" TYPE="REFERENCE">Vickers 2005</LINK>). Only one paper (<LINK REF="STD-Ta-and-Dionne-2004" TYPE="STUDY">Ta and Dionne 2004</LINK>) used ANCOVA to adjust for baseline values, which is the preferred method of analysing randomised trials with baseline and follow-up measures. The cross-over study by <LINK REF="STD-Tchivileva-et-al-2010" TYPE="STUDY">Tchivileva et al 2010</LINK> did not report pairwise differences between treatment arms.</P>
<P>Most studies included in this review reported means, which may not accurately represent patients' experience, and may obscure significant benefit in some individuals. Responder analysis is shown to be more useful in studying pain relief (<LINK REF="REF-Moore-2010b" TYPE="REFERENCE">Moore 2010b</LINK>).</P>
<P>For chronic musculoskeletal pain it was shown that on a numerical rating scale (10- cm horizontal line with descriptors 'no pain' on the left and 'worst possible pain' at the far right) a change of score of -2.0 cm and a per cent change score of -33% were best associated with the concept of 'much better' improvement on the pain relief as a clinically important outcome (<LINK REF="REF-Salaffi-2004" TYPE="REFERENCE">Salaffi 2004</LINK>). Only studies by <LINK REF="STD-Kimos-et-al-2007" TYPE="STUDY">Kimos et al 2007</LINK> for 10- cm VAS scale (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>) and <LINK REF="STD-Lobo-et-al-2004" TYPE="STUDY">Lobo et al 2004</LINK> (<LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>) for the 10-point numerical analogue scale showed such clinically important differences. Initiative on Methods, Measurement and Pain Assessment in Clinical Trials (IMMPACT) suggested that a decrease in pain of 50% or more should be considered as substantially important treatment outcome (<LINK REF="REF-Dworkin-2008" TYPE="REFERENCE">Dworkin 2008</LINK>).  </P>
<P>The minimum trial duration was 7 days (<LINK REF="STD-Tchivileva-et-al-2010" TYPE="STUDY">Tchivileva et al 2010</LINK>), maximum 12 weeks (<LINK REF="STD-Nguyen-et-al-2001" TYPE="STUDY">Nguyen et al 2001</LINK>; <LINK REF="STD-Kimos-et-al-2007" TYPE="STUDY">Kimos et al 2007</LINK>) and median 4 weeks (<LINK REF="STD-Ekberg-et-al-1996" TYPE="STUDY">Ekberg et al 1996</LINK>; <LINK REF="STD-Winocur-et-al-2000" TYPE="STUDY">Winocur et al 2000</LINK>) and it may be too short an evaluation period for a chronic condition. It was suggested that comparability between studies may be jeopardized when comparing, for example, results from small, short studies with easily attained but inadequate outcomes with large, long duration studies with clinically relevant outcomes that are hard to attain (<LINK REF="REF-Moore-2010a" TYPE="REFERENCE">Moore 2010a</LINK>).</P>
<P>In the study by <LINK REF="STD-Ta-and-Dionne-2004" TYPE="STUDY">Ta and Dionne 2004</LINK>, naproxen was administered at a dose of 500 mg twice daily for 6 weeks and had the most significant pain reduction of all the drugs. None of the adverse effects were reported as severe and there were no drop outs from the study as a result. The study by <LINK REF="STD-Lobo-et-al-2004" TYPE="STUDY">Lobo et al 2004</LINK> showed topical methyl salicylate to also have significant efficacy over placebo in reducing pain in TMD. The study authors (<LINK REF="STD-Lobo-et-al-2004" TYPE="STUDY">Lobo et al 2004</LINK>) did not refer to any adverse events occurring with the use of the cream. Methyl salicylate applied topically has been shown to be relatively safe but systemic absorption can increase in the presence of skin damage, application over a large skin surface area or when applied for prolonged periods (<LINK REF="REF-Chan-1996" TYPE="REFERENCE">Chan 1996</LINK>).</P>
<P>Gabapentin is primarily an anticonvulsant drug, but in the study by <LINK REF="STD-Kimos-et-al-2007" TYPE="STUDY">Kimos et al 2007</LINK> it demonstrated a significant reduction of pain in the TMJs and masseter muscles over placebo. This is not unexpected as gabapentin has been demonstrated to be useful with neuropathic pain and post-herpetic neuralgia (<LINK REF="REF-Rose-and-Kam-2002" TYPE="REFERENCE">Rose and Kam 2002</LINK>). However, the prescribing of gabapentin for the management of pain associated with TMD is unlicensed in some countries, for example, the United Kingdom. In the study by <LINK REF="STD-Kimos-et-al-2007" TYPE="STUDY">Kimos et al 2007</LINK>, gabapentin was administered at a dose of 300 mg to 4200 mg once daily for 12 weeks. The upper limit of the dose of gabapentin used in this study is much higher than the 2400 mg maximum daily dose of gabapentin that is recommended for epilepsy in the British National Formulary (<LINK REF="REF-BNF-2006" TYPE="REFERENCE">BNF 2006</LINK>). The recommended doses for neuropathic pain were much lower (<LINK REF="REF-BNF-2006" TYPE="REFERENCE">BNF 2006</LINK>). Although there were four drop outs from the study by <LINK REF="STD-Kimos-et-al-2007" TYPE="STUDY">Kimos et al 2007</LINK> as a result of adverse effects, the type of adverse effects and the drug they occurred as a result of were not stated. It is worthy of note that the participants' global assessment of improvement on gabapentin was not statistically significant over placebo at the 5% significance level (<LINK REF="STD-Kimos-et-al-2007" TYPE="STUDY">Kimos et al 2007</LINK>).</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2010-09-07 12:23:23 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2010-09-07 12:22:41 +0100" MODIFIED_BY="[Empty name]">
<P>The objective of this systematic review was to assess the effectiveness of pharmacological interventions for pain in patients with temporomandibular disorders (TMD). Many of the drugs analysed in this review are commonly used for the management of pain in patients with TMD. Most trials had few participants. Currently, there is insufficient evidence to support or not support the effectiveness of the reported drugs for the management of pain due to TMD.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2010-09-07 12:23:23 +0100" MODIFIED_BY="[Empty name]">
<P>There is a need for more well-conducted randomised controlled trials (RCTs) in the management of TMD. These studies need to be clear in the reporting of allocation, blinding, sequence generation, withdrawals, intention-to-treat analysis and any other potential source of bias in the study. In addition, well-validated standardised outcomes should be used so that the RCTs could be compared with other similar trials and meta-analysis conducted if needed. The sample size of the RCTs should also be calculated beforehand to ensure that the study has adequate statistical power.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2010-09-07 12:23:59 +0100" MODIFIED_BY="[Empty name]">
<P>The review authors would like to thank the staff of the University of Aberdeen medical library in general, and Ms Melanie Bickerton in particular, for help with reference retrieval and the search strategy. We are very grateful to Ms Anne Littlewood, Trials Search Co-ordinator, Cochrane Oral Health Group for help in updating the literature searches and adding the Cochrane Oral Health Group's Trials Register search strategy to the review.<BR/>
</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2010-09-06 17:20:58 +0100" MODIFIED_BY="[Empty name]">
<P>None.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2010-09-07 12:25:11 +0100" MODIFIED_BY="[Empty name]">
<P>Margaret Watson (MW) and Tatiana Macfarlane (TM) supervised Helen Mujakperuo (HM) as part of the Clinical Pharmacology MSc Project at the University of Aberdeen. HM conducted electronic searching and handsearching, entered the data into SPSS, contacted experts for identifying additional trials and contacted trial investigators for additional data. HM, MW, TM performed study selection, data extraction and methodological assessments. HM wrote the first draft and made figures. MW provided pharmacological input, TM statistical and epidemiological input and Roderick Morrison (RM) provided clinical expertise. All authors read and commented on the final draft. </P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2010-09-06 17:21:36 +0100" MODIFIED_BY="[Empty name]">
<P>According to the protocol, all participants should have had moderate to severe pain of minimum 3 months duration at the time of entering the trial. However, due to the limited number of studies which could be included in this review, all relevant studies were included but analysed on the basis of pain duration (minimum of 3 months pain duration, variable duration of pain, and unknown duration of pain). In addition, quality assessment criteria described in the protocol was replaced with risk of bias assessment.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2010-09-06 14:56:57 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2010-09-06 14:33:36 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2010-09-06 13:58:51 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Ekberg-et-al-1996" MODIFIED="2010-09-06 13:46:36 +0100" MODIFIED_BY="[Empty name]" NAME="Ekberg et al 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-09-06 13:46:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ekberg E, Kopp S, Akerman S</AU>
<TI>Diclofenac sodium as an alternative treatment of temporomandibular joint pain</TI>
<SO>Acta Odontologica Scandinavica</SO>
<YR>1996</YR>
<VL>54</VL>
<PG>154-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harkins-et-al-1991" MODIFIED="2010-09-06 13:47:53 +0100" MODIFIED_BY="[Empty name]" NAME="Harkins et al 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-09-06 13:47:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harkins S, Linford J, Cohen J, Kramer T, Cueva L</AU>
<TI>Administration of clonazepam in the treatment of TMD and associated myofascial pain: a double-blind pilot study</TI>
<SO>Journal of Craniomandibular Disorders: Facial &amp; Oral Pain</SO>
<YR>1991</YR>
<VL>5</VL>
<PG>179-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Herman-et-al-2002" MODIFIED="2010-09-06 13:48:47 +0100" MODIFIED_BY="[Empty name]" NAME="Herman et al 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-09-06 13:48:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Herman CR, Schiffman EL, Look JO, Rindal DB</AU>
<TI>The effectiveness of adding pharmacologic treatment with clonazepam or cyclobenzaprine to patient education and self-care for the treatment of jaw pain upon awakening: a randomized clinical trial</TI>
<SO>Journal of Orofacial Pain</SO>
<YR>2002</YR>
<VL>16</VL>
<PG>64-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kimos-et-al-2007" MODIFIED="2010-09-06 13:49:37 +0100" MODIFIED_BY="[Empty name]" NAME="Kimos et al 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-09-06 13:49:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kimos P, Biggs C, Mah J, Heo G, Rashiq S, Thie NMR et al</AU>
<TI>Analgesic action of gabapentin on chronic pain in the masticatory muscles: a randomized controlled trial</TI>
<SO>Pain</SO>
<YR>2007</YR>
<VL>127</VL>
<PG>151-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lobo-et-al-2004" MODIFIED="2010-09-06 13:50:54 +0100" MODIFIED_BY="[Empty name]" NAME="Lobo et al 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-09-06 13:50:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lobo S, Mehta N, Forgione AG, Melis M, Al-Badawi E, Ceneviz C et al</AU>
<TI>Use of Theraflex-TMJ topical cream for the treatment of temporomandibular joint and muscle pain</TI>
<SO>Cranio: the Journal of Craniomandibular Practice</SO>
<YR>2004</YR>
<VL>22</VL>
<PG>137-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nguyen-et-al-2001" MODIFIED="2010-09-06 13:55:46 +0100" MODIFIED_BY="[Empty name]" NAME="Nguyen et al 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-09-06 13:55:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nguyen P, Mohamed SE, Gardiner D, Salinas T</AU>
<TI>A randomized double-blind clinical trial of the effect of chondroitin sulfate and glucosamine hydrochloride on temporomandibular joint disorders: a pilot study</TI>
<SO>Cranio: the Journal of Craniomandibular Practice</SO>
<YR>2001</YR>
<VL>19</VL>
<PG>130-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roldan-et-al-1990" MODIFIED="2010-09-06 13:56:27 +0100" MODIFIED_BY="[Empty name]" NAME="Roldan et al 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-09-06 13:56:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roldan OV, Maglione H, Carreira R, Mainieri S</AU>
<TI>Piroxicam, diazepam and placebo in the treatment of temporomandibular joint dysfunction. Double blind study</TI>
<SO>Revista de la Asociacion Odontologica Argentina</SO>
<YR>1990</YR>
<VL>78</VL>
<PG>83-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rossi-et-al-1983" MODIFIED="2010-09-06 13:56:55 +0100" MODIFIED_BY="[Empty name]" NAME="Rossi et al 1983" YEAR="1983">
<REFERENCE MODIFIED="2010-09-06 13:56:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rossi E, Gallardo F, Weil MW</AU>
<TI>Prazepam as the initial treatment of myofascial pain-dysfunction syndrome</TI>
<SO>IRCS Medical Science</SO>
<YR>1983</YR>
<VL>11</VL>
<PG>637-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ta-and-Dionne-2004" MODIFIED="2010-09-06 13:57:24 +0100" MODIFIED_BY="[Empty name]" NAME="Ta and Dionne 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-09-06 13:57:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ta LE, Dionne RA</AU>
<TI>Treatment of painful temporomandibular joints with a cyclooxygenase-2 inhibitor: a randomized placebo-controlled comparison of celecoxib to naproxen</TI>
<SO>Pain</SO>
<YR>2004</YR>
<VL>111</VL>
<PG>13-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tchivileva-et-al-2010" MODIFIED="2010-09-06 13:57:49 +0100" MODIFIED_BY="[Empty name]" NAME="Tchivileva et al 2010" YEAR="2010">
<REFERENCE MODIFIED="2010-09-06 13:57:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tchivileva IE, Lim PF, Smith SB, Slade GD, Diatchenko L, McLean SA et al</AU>
<TI>Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study</TI>
<SO>Pharmacogenetics &amp; Genomics</SO>
<YR>2010</YR>
<VL>20</VL>
<NO>4</NO>
<PG>239-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Winocur-et-al-2000" MODIFIED="2010-09-06 13:58:51 +0100" MODIFIED_BY="[Empty name]" NAME="Winocur et al 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-09-06 13:58:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Winocur E, Gavish A, Halachmi M, Eli I, Gazit E</AU>
<TI>Topical application of capsaicin for the treatment of localized pain in the temporomandibular joint area</TI>
<SO>Journal of Orofacial Pain</SO>
<YR>2000</YR>
<VL>14</VL>
<PG>31-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2010-09-06 14:33:36 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bjorne-and-Agerberg-2003" MODIFIED="2010-09-06 13:59:41 +0100" MODIFIED_BY="[Empty name]" NAME="Bjorne and Agerberg 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-09-06 13:59:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bjorne A, Agerberg G</AU>
<TI>Symptom relief after treatment of temporomandibular and cervical spine disorders in patients with Meniere's disease: a three-year follow-up</TI>
<SO>Cranio: the Journal of Craniomandibular Practice</SO>
<YR>2003</YR>
<VL>21</VL>
<PG>50-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dao-et-al-1995" MODIFIED="2010-09-06 14:00:26 +0100" MODIFIED_BY="[Empty name]" NAME="Dao et al 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-09-06 14:00:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dao TT, Lund JP, Remillard G, Lavigne GJ</AU>
<TI>Is myofascial pain of the temporal muscles relieved by oral sumatriptan? A cross-over pilot study</TI>
<SO>Pain</SO>
<YR>1995</YR>
<VL>62</VL>
<PG>241-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DeNucci-et-al-1998" MODIFIED="2010-09-06 14:01:16 +0100" MODIFIED_BY="[Empty name]" NAME="DeNucci et al 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-09-06 14:01:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>DeNucci DJ, Sobiski C, Dionne RA</AU>
<TI>Triazolam improves sleep but fails to alter pain in TMD patients</TI>
<SO>Journal of Orofacial Pain</SO>
<YR>1998</YR>
<VL>12</VL>
<PG>116-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Di-Rienzo-Businco-2004" MODIFIED="2010-09-06 14:02:29 +0100" MODIFIED_BY="[Empty name]" NAME="Di Rienzo Businco 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-09-06 14:02:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Di Rienzo Businco L, Di Rienzo Businco A, D'Emilia M, Lauriello M, Coen Tirelli G</AU>
<TI>Topical versus systemic diclofenac in the treatment of temporo-mandibular joint dysfunction symptoms</TI>
<SO>Acta Otorhinolaryngologica Italica</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>5</NO>
<PG>279-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Epstein-et-al-1997" MODIFIED="2010-09-06 14:02:59 +0100" MODIFIED_BY="[Empty name]" NAME="Epstein et al 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-09-06 14:02:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Epstein JB, Grushka M, Le N</AU>
<TI>Topical clonidine for orofacial pain: a pilot study</TI>
<SO>Journal of Orofacial Pain</SO>
<YR>1997</YR>
<VL>11</VL>
<NO>4</NO>
<PG>346-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feinmann-1983" MODIFIED="2010-09-06 14:03:22 +0100" MODIFIED_BY="[Empty name]" NAME="Feinmann 1983" YEAR="1983">
<REFERENCE MODIFIED="2010-09-06 14:03:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feinmann C</AU>
<TI>Psychogenic facial pain: presentation and treatment</TI>
<SO>Journal of Psychosomatic Research</SO>
<YR>1983</YR>
<VL>27</VL>
<PG>403-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Franks-1965" MODIFIED="2010-09-06 14:03:49 +0100" MODIFIED_BY="[Empty name]" NAME="Franks 1965" YEAR="1965">
<REFERENCE MODIFIED="2010-09-06 14:03:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Franks AS</AU>
<TI>Mandibular muscle spasm. A double-blind study of a muscle relaxant drug</TI>
<SO>The British Journal of Clinical Practice</SO>
<YR>1965</YR>
<VL>19</VL>
<PG>281-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gallardo-et-al-1975" MODIFIED="2010-09-06 14:04:22 +0100" MODIFIED_BY="[Empty name]" NAME="Gallardo et al 1975" YEAR="1975">
<REFERENCE MODIFIED="2010-09-06 14:04:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gallardo F, Molgo J, Miyazaki C, Rossi E</AU>
<TI>Carisoprodol in the treatment of myofascial pain dysfunction syndrome</TI>
<SO>Journal of Oral Surgery</SO>
<YR>1975</YR>
<VL>33</VL>
<PG>655-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gaudet-and-Brown-2000" MODIFIED="2010-09-06 14:05:32 +0100" MODIFIED_BY="[Empty name]" NAME="Gaudet and Brown 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-09-06 14:05:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gaudet EL Jr, Brown DT</AU>
<TI>Temporomandibular disorder treatment outcomes: first report of a large-scale prospective clinical study</TI>
<SO>Cranio: the Journal of Craniomandibular Practice</SO>
<YR>2000</YR>
<VL>18</VL>
<PG>9-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gerschman-et-al-1984" MODIFIED="2010-09-06 14:06:34 +0100" MODIFIED_BY="[Empty name]" NAME="Gerschman et al 1984" YEAR="1984">
<REFERENCE MODIFIED="2010-09-06 14:06:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gerschman JA, Reade PD, Burrows GD</AU>
<TI>Evaluation of a proprietary analgesic/antihistamine in the management of pain associated with temporomandibular joint pain dysfunction syndrome</TI>
<SO>Australian Dental Journal</SO>
<YR>1984</YR>
<VL>29</VL>
<PG>300-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gessel-1975" MODIFIED="2010-09-06 14:07:14 +0100" MODIFIED_BY="[Empty name]" NAME="Gessel 1975" YEAR="1975">
<REFERENCE MODIFIED="2010-09-06 14:07:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gessel AH</AU>
<TI>Electromygraphic biofeedback and tricyclic antidepressants in myofascial pain-dysfunction syndrome: psychological predictors of outcome</TI>
<SO>The Journal of the American Dental Association</SO>
<YR>1975</YR>
<VL>91</VL>
<PG>1048-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greene-and-Laskin-1971" MODIFIED="2010-09-06 14:07:40 +0100" MODIFIED_BY="[Empty name]" NAME="Greene and Laskin 1971" YEAR="1971">
<REFERENCE MODIFIED="2010-09-06 14:07:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greene CS, Laskin DM</AU>
<TI>Meprobamate therapy for the myofascial pain-dysfunction (MPD) syndrome: a double-blind evaluation</TI>
<SO>The Journal of the American Dental Association</SO>
<YR>1971</YR>
<VL>82</VL>
<PG>587-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greene-and-Laskin-1974" MODIFIED="2010-09-06 14:08:08 +0100" MODIFIED_BY="[Empty name]" NAME="Greene and Laskin 1974" YEAR="1974">
<REFERENCE MODIFIED="2010-09-06 14:08:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greene CS, Laskin DM</AU>
<TI>Long-term evaluation of conservative treatment for myofascial pain-dysfunction syndrome</TI>
<SO>The Journal of the American Dental Association</SO>
<YR>1974</YR>
<VL>89</VL>
<PG>1365-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hodosh-et-al-2007" MODIFIED="2010-09-06 14:08:48 +0100" MODIFIED_BY="[Empty name]" NAME="Hodosh et al 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-09-06 14:08:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hodosh M</AU>
<TI>A new, noninvasive approach for successfully treating the pain and inflammation of TMJ disorders</TI>
<SO>The Journal of Oral Implantology</SO>
<YR>2007</YR>
<VL>33</VL>
<PG>365-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jagger-1973" MODIFIED="2010-09-06 14:09:26 +0100" MODIFIED_BY="[Empty name]" NAME="Jagger 1973" YEAR="1973">
<REFERENCE MODIFIED="2010-09-06 14:09:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jagger RG</AU>
<TI>Diazepam in the treatment of temporomandibular joint dysfunction syndrome - a double blind study</TI>
<SO>Journal of Dentistry</SO>
<YR>1973</YR>
<VL>2</VL>
<PG>37-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lipp-et-al-1989" MODIFIED="2010-09-06 14:10:43 +0100" MODIFIED_BY="[Empty name]" NAME="Lipp et al 1989" YEAR="">
<REFERENCE MODIFIED="2010-09-06 14:10:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lipp M, Dick W, Daublander M, Gervais H, Kutter C</AU>
<TI>Effects of muscle relaxants on temporomandibular joint movements and dysfunctions</TI>
<SO>European Journal of Anaesthesiology</SO>
<YR>1989</YR>
<VL>6</VL>
<PG>454</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martani-et-al-1968" MODIFIED="2010-09-06 14:11:23 +0100" MODIFIED_BY="[Empty name]" NAME="Martani et al 1968" YEAR="1968">
<REFERENCE MODIFIED="2010-09-06 14:11:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martani F, Cuppini A, Gelli M</AU>
<TI>Effects of synthetic corticosteroids on the level of the temporomandibular joint. (Clinical contribution--distant controls)</TI>
<SO>Mondo Odontostomatologico</SO>
<YR>1968</YR>
<VL>10</VL>
<PG>574-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mejersjo-Wenneberg-2008" MODIFIED="2010-09-06 14:11:58 +0100" MODIFIED_BY="[Empty name]" NAME="Mejersjo Wenneberg 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-09-06 14:11:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mejersjo C, Wenneberg B</AU>
<TI>Diclofenac sodium and occlusal splint therapy in TMJ osteoarthritis: a randomized controlled trial</TI>
<SO>Journal of Oral Rehabilitation</SO>
<YR>2008</YR>
<VL>35</VL>
<PG>729-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Minakuchi-et-al-2001" MODIFIED="2010-09-06 14:12:55 +0100" MODIFIED_BY="[Empty name]" NAME="Minakuchi et al 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-09-06 14:12:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Minakuchi H, Kuboki T, Matsuka Y, Maekawa K, Yatani H, Yamashita A</AU>
<TI>Randomized controlled evaluation of non-surgical treatments for temporomandibular joint anterior disk displacement without reduction</TI>
<SO>Journal of Dental Research</SO>
<YR>2001</YR>
<VL>80</VL>
<PG>924-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mongini-et-al-1993" MODIFIED="2010-09-06 14:13:30 +0100" MODIFIED_BY="[Empty name]" NAME="Mongini et al 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-09-06 14:13:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mongini F, Bona G, Garnero M, Gioria A</AU>
<TI>Efficacy of meclofenamate sodium versus placebo in headache and craniofacial pain</TI>
<SO>Headache</SO>
<YR>1993</YR>
<VL>33</VL>
<PG>22-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Murakami-et-al-1995" MODIFIED="2010-09-06 14:14:30 +0100" MODIFIED_BY="[Empty name]" NAME="Murakami et al 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-09-06 14:14:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Murakami K, Hosaka H, Moriya Y, Segami N, Iizuka T</AU>
<TI>Short-term treatment outcome study for the management of temporomandibular joint closed lock. A comparison of arthrocentesis to nonsurgical therapy and arthroscopic lysis and lavage</TI>
<SO>Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontics</SO>
<YR>1995</YR>
<VL>80</VL>
<PG>253-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nekora_x002d_Azak-et-al-2008" MODIFIED="2010-09-06 14:16:04 +0100" MODIFIED_BY="[Empty name]" NAME="Nekora-Azak et al 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-09-06 14:16:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nekora-Azak A, Evlioglu G, Ceyhan A, Keskin H, Berkman S, Issever H</AU>
<TI>Estrogen replacement therapy among postmenopausal women and its effects on signs and symptoms of temporomandibular disorders</TI>
<SO>Cranio: the Journal of Craniomandibular Practice</SO>
<YR>2008</YR>
<VL>26</VL>
<PG>211-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nemcovsky-et-al-1992" MODIFIED="2010-09-06 14:18:23 +0100" MODIFIED_BY="[Empty name]" NAME="Nemcovsky et al 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-09-06 14:18:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nemcovsky CE, Gazit E, Serfati V, Gross M</AU>
<TI>A comparative study of three therapeutic modalities in a temporomandibular disorder (TMD) population</TI>
<SO>Cranio: the Journal of Craniomandibular Practice</SO>
<YR>1992</YR>
<VL>10</VL>
<PG>148-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Plesh-et-al-2000" MODIFIED="2010-09-06 14:19:07 +0100" MODIFIED_BY="[Empty name]" NAME="Plesh et al 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-09-06 14:19:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Plesh O, Curtis D, Levine J, McCall WD Jr</AU>
<TI>Amitriptyline treatment of chronic pain in patients with temporomandibular disorders</TI>
<SO>Journal of Oral Rehabilitation</SO>
<YR>2000</YR>
<VL>27</VL>
<PG>834-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rizzatti_x002d_Barbosa-2003a" MODIFIED="2010-09-06 14:22:21 +0100" MODIFIED_BY="[Empty name]" NAME="Rizzatti-Barbosa 2003a" YEAR="2003">
<REFERENCE MODIFIED="2010-09-06 14:21:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rizzatti-Barbosa CM, Martinelli DA, Ambrosano GMB, de Albergaria-Barbosa JR</AU>
<TI>Therapeutic response of benzodiazepine, orphenadrine citrate and occlusal splint association in TMD pain</TI>
<SO>Cranio: the Journal of Craniomandibular Practice</SO>
<YR>2003</YR>
<VL>21</VL>
<PG>116-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rizzatti_x002d_Barbosa-2003b" MODIFIED="2010-09-06 14:24:03 +0100" MODIFIED_BY="[Empty name]" NAME="Rizzatti-Barbosa 2003b" YEAR="2003">
<REFERENCE MODIFIED="2010-09-06 14:24:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rizzatti-Barbosa CM, Nogueira MT, de Andrade ED, Ambrosano GM, de Barbosa JR</AU>
<TI>Clinical evaluation of amitriptyline for the control of chronic pain caused by temporomandibular joint disorders</TI>
<SO>Cranio: the Journal of Craniomandibular Practice</SO>
<YR>2003</YR>
<VL>21</VL>
<PG>221-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schwartz-et-al-1996" MODIFIED="2010-09-06 14:25:11 +0100" MODIFIED_BY="[Empty name]" NAME="Schwartz et al 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-09-06 14:25:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schwartz G, Galonski M, Gordon A, Shandling M, Mock D, Tenenbaum HC</AU>
<TI>Effects of salmon calcitonin on patients with atypical (idiopathic) facial pain: a randomized controlled trial</TI>
<SO>Journal of Orofacial Pain</SO>
<YR>1996</YR>
<VL>10</VL>
<PG>306-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shankland-1998" MODIFIED="2010-09-06 14:25:56 +0100" MODIFIED_BY="[Empty name]" NAME="Shankland 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-09-06 14:25:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shankland WE 2nd</AU>
<TI>The effects of glucosamine and chondroitin sulfate on osteoarthritis of the TMJ: a preliminary report of 50 patients</TI>
<SO>Cranio: the Journal of Craniomandibular Practice</SO>
<YR>1998</YR>
<VL>16</VL>
<PG>230-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shiffman-et-al-1996" MODIFIED="2010-09-06 14:26:32 +0100" MODIFIED_BY="[Empty name]" NAME="Shiffman et al 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-09-06 14:26:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schiffman EL, Braun BL, Lindgren BR</AU>
<TI>Temporomandibular joint iontophoresis: a double-blind randomized clinical trial</TI>
<SO>Journal of Orofacial Pain</SO>
<YR>1996</YR>
<VL>10</VL>
<PG>157-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shin-and-Choi-1997" MODIFIED="2010-09-06 14:27:22 +0100" MODIFIED_BY="[Empty name]" NAME="Shin and Choi 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-09-06 14:27:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shin SM, Choi JK</AU>
<TI>Effect of indomethacin phonophoresis on the relief of temporomandibular joint pain</TI>
<SO>Cranio: the Journal of Craniomandibular Practice</SO>
<YR>1997</YR>
<VL>15</VL>
<PG>345-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Singer-and-Dionne-1997" MODIFIED="2010-09-06 14:27:53 +0100" MODIFIED_BY="[Empty name]" NAME="Singer and Dionne 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-09-06 14:27:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Singer E, Dionne R</AU>
<TI>A controlled evaluation of ibuprofen and diazepam for chronic orofacial muscle pain</TI>
<SO>Journal of Orofacial Pain</SO>
<YR>1997</YR>
<VL>11</VL>
<PG>139-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stiesch_x002d_Scholz-et-al-2002" MODIFIED="2010-09-06 14:29:14 +0100" MODIFIED_BY="[Empty name]" NAME="Stiesch-Scholz et al 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-09-06 14:29:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stiesch-Scholz M, Fink M, Tschernitschek H, Rossbach A</AU>
<TI>Medical and physical therapy of temporomandibular joint disk displacement without reduction</TI>
<SO>Cranio: the Journal of Craniomandibular Practice</SO>
<YR>2002</YR>
<VL>20</VL>
<PG>85-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thie-et-al-2001" MODIFIED="2010-09-06 14:29:53 +0100" MODIFIED_BY="[Empty name]" NAME="Thie et al 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-09-06 14:29:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thie NM, Prasad NG, Major PW</AU>
<TI>Evaluation of glucosamine sulfate compared to ibuprofen for the treatment of temporomandibular joint osteoarthritis: a randomized double blind controlled 3 month clinical trial</TI>
<SO>Journal of Rheumatology</SO>
<YR>2001</YR>
<VL>28</VL>
<PG>1347-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tversky-et-al-1991" MODIFIED="2010-09-06 14:30:48 +0100" MODIFIED_BY="[Empty name]" NAME="Tversky et al 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-09-06 14:30:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tversky J, Reade PC, Gerschman JA, Holwill BJ, Wright J</AU>
<TI>Role of depressive illness in the outcome of treatment of temporomandibular joint pain-dysfunction syndrome</TI>
<SO>Oral Surgery, Oral Medicine, and Oral Pathology</SO>
<YR>1991</YR>
<VL>71</VL>
<PG>696-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-der-Berghe-et-al-1986" MODIFIED="2010-09-06 14:32:16 +0100" MODIFIED_BY="[Empty name]" NAME="van der Berghe et al 1986" YEAR="1986">
<REFERENCE MODIFIED="2010-09-06 14:32:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van der Berghe LI, de Boever JA, Schautteet HA</AU>
<TI>Double-blind clinical study of Piroxicam as adjuvant in the treatment of the pain and dysfunction of the temporomandibular joints</TI>
<SO>Cranio: the Journal of Craniomandibular Practice</SO>
<YR>1986</YR>
<VL>4</VL>
<PG>351-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Volinier-and-Bianchi-1967" MODIFIED="2010-09-06 14:32:51 +0100" MODIFIED_BY="[Empty name]" NAME="Volinier and Bianchi 1967" YEAR="1967">
<REFERENCE MODIFIED="2010-09-06 14:32:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Volinier RM, Bianchi DH</AU>
<TI>Dexamethasone in dysfunctions of the temporomandibular joint. Preliminary note with 50 cases</TI>
<SO>Anales Espanoles de Odontoestomatologia</SO>
<YR>1967</YR>
<VL>26</VL>
<PG>314-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zander-et-al-1982" MODIFIED="2010-09-06 14:33:36 +0100" MODIFIED_BY="[Empty name]" NAME="Zander et al 1982" YEAR="1982">
<REFERENCE MODIFIED="2010-09-06 14:33:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zander A, Buddeberg C, Frei R</AU>
<TI>Treatment of mandibular dysfunction: a comparative therapeutic study</TI>
<SO>SSO Schweizerische Monatsschrift fur Zahnheilkunde</SO>
<YR>1982</YR>
<VL>92</VL>
<PG>515-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2010-09-06 14:56:57 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2010-09-06 14:56:57 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-BNF-2006" MODIFIED="2010-09-06 14:35:05 +0100" MODIFIED_BY="[Empty name]" NAME="BNF 2006" TYPE="OTHER">
<AU>British National Formulary</AU>
<TI>British National Formulary. Issue 51</TI>
<SO>Available from http://bnf.org/bnf/index.htm</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Borodic-2002" MODIFIED="2010-09-06 14:35:34 +0100" MODIFIED_BY="[Empty name]" NAME="Borodic 2002" TYPE="JOURNAL_ARTICLE">
<AU>Borodic GE, Acquadro MA</AU>
<TI>The use of botulinum toxin for the treatment of chronic facial pain</TI>
<SO>Journal of Pain</SO>
<YR>2002</YR>
<VL>3</VL>
<PG>21-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chan-1996" MODIFIED="2010-09-06 14:36:56 +0100" MODIFIED_BY="[Empty name]" NAME="Chan 1996" TYPE="JOURNAL_ARTICLE">
<AU>Chan TY</AU>
<TI>Potential dangers from topical preparations containing methyl salicylate</TI>
<SO>Human and Experimental Toxicology</SO>
<YR>1996</YR>
<VL>15</VL>
<PG>747-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dimitroulis-1998" MODIFIED="2010-09-06 14:39:07 +0100" MODIFIED_BY="[Empty name]" NAME="Dimitroulis 1998" TYPE="JOURNAL_ARTICLE">
<AU>Dimitroulis G</AU>
<TI>Temporomandibular disorders: a clinical update</TI>
<SO>BMJ</SO>
<YR>1998</YR>
<VL>317</VL>
<PG>190-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dionne-1997" MODIFIED="2010-09-06 14:39:41 +0100" MODIFIED_BY="[Empty name]" NAME="Dionne 1997" TYPE="JOURNAL_ARTICLE">
<AU>Dionne RA</AU>
<TI>Pharmacologic treatments for temporomandibular disorders</TI>
<SO>Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics</SO>
<YR>1997</YR>
<VL>83</VL>
<PG>134-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dworkin-2008" MODIFIED="2010-09-06 14:40:34 +0100" MODIFIED_BY="[Empty name]" NAME="Dworkin 2008" TYPE="JOURNAL_ARTICLE">
<AU>Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT et al</AU>
<TI>Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations</TI>
<SO>Journal of Pain</SO>
<YR>2008</YR>
<VL>9</VL>
<PG>105-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-et-al-2002" MODIFIED="2010-09-06 14:41:02 +0100" MODIFIED_BY="[Empty name]" NAME="Elbourne et al 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV,Vail A</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<PG>140&#8211;9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guo-et-al-2009" MODIFIED="2010-09-06 14:38:23 +0100" MODIFIED_BY="[Empty name]" NAME="Guo et al 2009" TYPE="COCHRANE_REVIEW">
<AU>Guo C, Shi Z, Revington P</AU>
<TI>Arthrocentesis and lavage for treating temporomandibular joint disorders</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2010-09-06 14:38:23 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-06 14:38:23 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004973.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hersh-et-al-2008" MODIFIED="2010-09-06 14:41:56 +0100" MODIFIED_BY="[Empty name]" NAME="Hersh et al 2008" TYPE="JOURNAL_ARTICLE">
<AU>Hersh EV, Balasubramaniam R, Pinto A</AU>
<TI>Pharmacologic management of temporomandibular disorders</TI>
<SO>Oral and Maxillofacial Surgery Clinics of North America</SO>
<YR>2008</YR>
<VL>20</VL>
<PG>197-210</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2009" MODIFIED="2010-09-06 14:44:05 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2009" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions version 5.0.2 (updated September 2009). The Cochrane Collaboration, 2009</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Luther-2007" MODIFIED="2010-09-06 14:44:32 +0100" MODIFIED_BY="[Empty name]" NAME="Luther 2007" TYPE="JOURNAL_ARTICLE">
<AU>Luther F</AU>
<TI>TMD and occlusion part II. Damned if we don't? Functional occlusal problems: TMD epidemiology in a wider context</TI>
<SO>British Dental Journal</SO>
<YR>2007</YR>
<VL>202</VL>
<PG>E3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Manfredini-et-al-2006" MODIFIED="2010-09-06 14:45:29 +0100" MODIFIED_BY="[Empty name]" NAME="Manfredini et al 2006" TYPE="JOURNAL_ARTICLE">
<AU>Manfredini D, Chiappe G, Bosco M</AU>
<TI>Research diagnostic criteria for temporomandibular disorders (RDC/TMD) axis I diagnoses in an Italian patient population</TI>
<SO>Journal of Oral Rehabilitation</SO>
<YR>2006</YR>
<VL>33</VL>
<PG>551-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McNeill-1997" MODIFIED="2010-09-06 14:46:05 +0100" MODIFIED_BY="[Empty name]" NAME="McNeill 1997" TYPE="JOURNAL_ARTICLE">
<AU>McNeill C</AU>
<TI>History and evolution of TMD concepts</TI>
<SO>Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics</SO>
<YR>1997</YR>
<VL>83</VL>
<PG>51-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-et-al-2001" MODIFIED="2010-09-06 14:49:14 +0100" MODIFIED_BY="[Empty name]" NAME="Moher et al 2001" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Schulz KF, Altman DG</AU>
<TI>The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2001</YR>
<VL>1</VL>
<PG>2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-2010a" MODIFIED="2010-09-06 14:50:44 +0100" MODIFIED_BY="[Empty name]" NAME="Moore 2010a" TYPE="OTHER">
<AU>Moore RA, Eccleston C, Derry S, Wiffen P, Bell RF, Straube S et al</AU>
<TI>"Evidence" in chronic pain - establishing best practice in the reporting of systematic reviews</TI>
<SO>Pain</SO>
<YR>in press</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-2010b" MODIFIED="2010-09-06 14:51:22 +0100" MODIFIED_BY="[Empty name]" NAME="Moore 2010b" TYPE="JOURNAL_ARTICLE">
<AU>Moore RA, Moore OA, Derry S, Peloso PM, Gammaitoni AR, Wang H</AU>
<TI>Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2010</YR>
<VL>69</VL>
<PG>374-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Okeson-1997" MODIFIED="2010-09-06 14:51:51 +0100" MODIFIED_BY="[Empty name]" NAME="Okeson 1997" TYPE="JOURNAL_ARTICLE">
<AU>Okeson JP</AU>
<TI>Current terminology and diagnostic classification schemes</TI>
<SO>Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics</SO>
<YR>1997</YR>
<VL>83</VL>
<PG>61-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Revman5" MODIFIED="2010-09-06 14:56:57 +0100" MODIFIED_BY="[Empty name]" NAME="Revman5" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan) Version 5.0</TI>
<YR>2008</YR>
<PB>Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rose-and-Kam-2002" MODIFIED="2010-09-06 14:52:29 +0100" MODIFIED_BY="[Empty name]" NAME="Rose and Kam 2002" TYPE="JOURNAL_ARTICLE">
<AU>ROSE MA, KAM PC</AU>
<TI>Gabapentin: pharmacology and its use in pain management</TI>
<SO>Anaesthesia</SO>
<YR>2002</YR>
<VL>57</VL>
<PG>451-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Salaffi-2004" MODIFIED="2010-09-06 14:52:54 +0100" MODIFIED_BY="[Empty name]" NAME="Salaffi 2004" TYPE="JOURNAL_ARTICLE">
<AU>Salaffi F, Stancati A, Silvestri CA, Ciapetti A, Grassi W</AU>
<TI>Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale</TI>
<SO>European Journal of Pain</SO>
<YR>2004</YR>
<VL>8</VL>
<PG>283-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shi-et-al-2003" MODIFIED="2010-09-06 14:53:54 +0100" MODIFIED_BY="[Empty name]" NAME="Shi et al 2003" TYPE="COCHRANE_REVIEW">
<AU>Shi Z, Guo C, Awad M</AU>
<TI>Hyaluronate for temporomandibular joint disorders</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2010-09-06 14:53:33 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-06 14:53:33 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002970"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Song-et-al-2007" MODIFIED="2010-09-06 14:54:41 +0100" MODIFIED_BY="[Empty name]" NAME="Song et al 2007" TYPE="JOURNAL_ARTICLE">
<AU>Song PC, Schwartz J, Blitzer A</AU>
<TI>The emerging role of botulinum toxin in the treatment of temporomandibular disorders</TI>
<SO>Oral Diseases</SO>
<YR>2007</YR>
<VL>13</VL>
<PG>253-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vickers-2005" MODIFIED="2010-09-06 14:55:05 +0100" MODIFIED_BY="[Empty name]" NAME="Vickers 2005" TYPE="JOURNAL_ARTICLE">
<AU>Vickers AJ</AU>
<TI>Parametric versus non-parametric statistics in the analysis of randomized trials with non-normally distributed data</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2005</YR>
<VL>5</VL>
<PG>35</PG>
<IDENTIFIERS MODIFIED="2010-06-25 14:56:39 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2010-09-06 17:11:34 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2010-09-06 16:44:30 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-09-06 15:20:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ekberg-et-al-1996">
<CHAR_METHODS MODIFIED="2010-09-06 15:19:06 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised double-blind placebo-controlled trial.</P>
<P>Single-centred with 2 parallel groups; follow-up for 4 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-06 15:19:23 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Sweden.</P>
<P>Inclusion criteria: Pain in the TMJ for at least 6 weeks; lateral or posterior tenderness to the TMJ. Age at least 20 years.</P>
<P>16 participants in the intervention group (diclofenac sodium) and 16 participants in the control group (placebo).</P>
<P>Sex: 5 male (15.6%); 27 female (84.4%).</P>
<P>Age: 27 to 82 years (mean 47 years).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-06 15:19:55 +0100" MODIFIED_BY="[Empty name]">
<P>Oral diclofenac sodium (NSAID) 50 mg 3 times daily for 1 week then 50 mg twice daily for 1 week (n = 16) or placebo (n = 16).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-06 15:20:24 +0100" MODIFIED_BY="[Empty name]">
<P>VAS assessment of daily TMJ pain and tenderness of 3 or more muscles of mastication on palpation of the masticatory muscles at baseline, week 2 (immediately after completing the drug) and week 4 (follow-up 2 weeks later).</P>
<P>Adverse reactions were reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-17 11:21:57 +0100" MODIFIED_BY="[Empty name]">
<P>Authors concluded that there was no evidence in this study to prove that diclofenac should be used as a primary treatment of TMJ pain. There was pharmaceutical industry sponsorship.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-06 15:22:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harkins-et-al-1991">
<CHAR_METHODS MODIFIED="2010-09-06 15:21:04 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised double-blind placebo-controlled trial.</P>
<P>Single-centred with 2 parallel groups; follow-up for 60 days.</P>
<P>Data complied for baseline and day 30 only due to high drop-out rate.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-06 15:21:24 +0100" MODIFIED_BY="[Empty name]">
<P>Location: USA.</P>
<P>Inclusion criteria: Patients with painful recurrent anterior disc dislocation in one or both TMJs of at least 3 months, limited jaw opening, myofascial pain in the temporalis/masseters.</P>
<P>10 participants in the intervention group (clonazepam) and 10 participants in the control group (placebo).</P>
<P>Sex: 2 male (20%); 18 female (80%).</P>
<P>Age: 18 to 48 years (mean age 31).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-06 15:21:30 +0100" MODIFIED_BY="[Empty name]">
<P>Oral clonazepam (benzodiazepine) 0.25 mg - 1 mg daily for 60 days (n = 10) or placebo (n = 10).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-06 15:21:56 +0100" MODIFIED_BY="[Empty name]">
<P>VAS assessment of pain on palpation of the right and left masseter muscles at baseline and at day 30.</P>
<P>Patients' assessment of improvement of pain levels in the right and left TMJ assessed on VAS at baseline and at day 30.</P>
<P>Adverse reactions were reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-06 15:22:04 +0100" MODIFIED_BY="[Empty name]">
<P>High drop-out rate after day 30. Data compiled for baseline and day 30. Pharmaceutical industry sponsorship unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-06 15:23:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Herman-et-al-2002">
<CHAR_METHODS MODIFIED="2010-09-06 15:22:51 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised double-blind placebo-controlled trial.</P>
<P>Single-centred with 3 parallel groups; follow-up for 3 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-06 15:23:12 +0100" MODIFIED_BY="[Empty name]">
<P>Location: USA.</P>
<P>Inclusion criteria: Jaw pain upon awakening, occurring a minimum of 2 days a week; RCD/TMD axis I myofascial pain; TMJ arthralgia/disc displacement with reduction.</P>
<P>13 participants in the first intervention group (clonazepam), 13 participants in the second intervention group (cyclobenzaprine) and 15 participants in the control group (placebo).</P>
<P>Sex: 8 male (19.5%); 33 female (80.5%).</P>
<P>Age: 18 to 65 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-06 15:23:39 +0100" MODIFIED_BY="[Empty name]">
<P>Oral clonazepam (benzodiazepine) 0.5 mg daily for 3 weeks (n = 13), oral cyclobenzaprine (muscle relaxant) 10 mg daily for 3 weeks (n = 13) or placebo (n = 15).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-06 15:23:53 +0100" MODIFIED_BY="[Empty name]">
<P>Jaw pain intensity assessed on a VAS at baseline and week 3.</P>
<P>Adverse reactions were reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-17 11:23:39 +0100" MODIFIED_BY="[Empty name]">
<P>Pharmaceutical industry sponsorship unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-06 15:26:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kimos-et-al-2007">
<CHAR_METHODS MODIFIED="2010-09-06 15:24:35 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised double-blind placebo-controlled trial.</P>
<P>Computer-generated randomisation.</P>
<P>Single-centred with 2 parallel groups; follow-up for 12 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-06 15:25:07 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Canada.</P>
<P>Inclusion criteria: Masticatory muscle pain for at least 6 months which is not secondary to trauma, infection or inflammation; baseline score of at least 50 mm on 100 mm VAS.</P>
<P>25 participants in the intervention group (gabapentin) and 25 participants in the control group (placebo).</P>
<P>Intention-to-treat analysis: 24 participants in intervention group and 20 participants in the placebo group.</P>
<P>Sex: 50 females (100%).</P>
<P>Age: 18 to 45 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-06 15:25:28 +0100" MODIFIED_BY="[Empty name]">
<P>Oral gabapentin (anticonvulsant) 300 mg to 4200 mg daily for 3 months (n = 24) or placebo (n = 20).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-06 15:26:04 +0100" MODIFIED_BY="[Empty name]">
<P>VAS assessment of spontaneous pain in the TMJ at baseline and week 12.</P>
<P>Number of tender sites in the TMJ at baseline and week 12.</P>
<P>Participants' assessment of function on a VAS at baseline and week 12.</P>
<P>Adverse reactions were reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-06 15:26:08 +0100" MODIFIED_BY="[Empty name]">
<P>Authors' conclusion was that gabapentin was effective for the management of chronic masticatory myalgia. Pharmaceutical industry sponsorship.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-06 15:27:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lobo-et-al-2004">
<CHAR_METHODS MODIFIED="2010-09-06 15:27:01 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised double-blind placebo-controlled trial.</P>
<P>Third party randomisation.</P>
<P>Single-centred with 2 parallel groups; follow-up for 20 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-06 15:27:10 +0100" MODIFIED_BY="[Empty name]">
<P>Location: USA.</P>
<P>Inclusion criteria: Patients with report of pain in the masseter muscles at rest or during function, pain on palpation of the masseter muscle or pain in the TMJ at rest or during function.</P>
<P>26 participants in the intervention group (theraflex TMJ) and 26 participants in the control group (placebo).</P>
<P>Sex: 5 male (9.6%); 47 female (90.4%).</P>
<P>Age: 18 to 60 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-06 15:27:25 +0100" MODIFIED_BY="[Empty name]">
<P>Theraflex-TMJ cream (NSAID) applied topically over the masseter muscles twice daily for 2 weeks (n = 26) or placebo cream (n = 26).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-06 15:27:30 +0100" MODIFIED_BY="[Empty name]">
<P>Numerical Graphic Rating scale assessment of spontaneous masseter muscle pain and TMJ pain were measured at baseline, day 10, day 15 and 5 days after stopping the medication.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-17 11:25:16 +0100" MODIFIED_BY="[Empty name]">
<P>Pain in the intervention group increased when the application was discontinued.</P>
<P>Significant risk of bias as study was sponsored by the company which produces the drug. Pharmaceutical industry sponsorship.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-06 15:28:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nguyen-et-al-2001">
<CHAR_METHODS MODIFIED="2010-09-06 15:27:57 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised double-blind placebo-controlled trial.</P>
<P>Single-centred with 2 parallel groups; follow-up for 3 months.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-06 15:28:29 +0100" MODIFIED_BY="[Empty name]">
<P>Location: USA.</P>
<P>Inclusion criteria: Complaints of pain in 1 or both temporomandibular joints; moderate or severe pain on lateral or dorsal palpation of the TMJ.</P>
<P>23 participants randomised to the intervention group (glucosamine hydrochloride/chondroitin sulphate) with 14 completing. 22 participants randomised to the control group (placebo) with 20 completing.</P>
<P>Sex: 4 male (11.8%); 30 female (88.2%).</P>
<P>Age: Intervention group (43 <U>+</U> 14), placebo group (46 <U>+</U> 15).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-06 15:28:35 +0100" MODIFIED_BY="[Empty name]">
<P>Oral glucosamine hydrochloride/chondroitin sulphate 750/600 mg twice daily for 3 months (n = 23) or placebo (n = 22).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-06 15:28:58 +0100" MODIFIED_BY="[Empty name]">
<P>Pain intensity measured on a VAS at baseline and at 12 weeks.</P>
<P>Total pain rating index assessed using McGill pain questionnaire at baseline and at 12 weeks.</P>
<P>Pain on palpation of the TMJ at baseline and at 12 weeks.</P>
<P>Overall global assessment of improvement at 12 weeks.</P>
<P>Adverse reactions were reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-17 11:25:42 +0100" MODIFIED_BY="[Empty name]">
<P>Pharmaceutical industry sponsorship unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-06 15:30:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Roldan-et-al-1990">
<CHAR_METHODS MODIFIED="2010-09-06 15:29:49 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised double-blind placebo-controlled trial.</P>
<P>Single-centred with 3 parallel groups; follow-up for 15 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-06 15:29:59 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Argentina.</P>
<P>Inclusion criteria: Dysfunction of somatognathic system; Helkimo clinical dysfunction index.</P>
<P>14 participants in the first intervention group (piroxicam), 15 participants in the second intervention group (diazepam) and 12 participants in the control group (placebo).</P>
<P>Sex: 18% male; 82% female.</P>
<P>Age: 18 to 70 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-06 15:30:21 +0100" MODIFIED_BY="[Empty name]">
<P>Oral piroxicam (NSAID) 20 mg daily for 15 days (n = 14), oral diazepam (benzodiazepine) 2 mg daily for 15 days (n = 15) or placebo (n = 12).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-06 15:30:23 +0100" MODIFIED_BY="[Empty name]">
<P>Severe somatognathic dysfunction assessed on day 15.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-10 00:52:00 +0100" MODIFIED_BY="[Empty name]">
<P>Pharmaceutical industry sponsorship unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-06 15:32:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rossi-et-al-1983">
<CHAR_METHODS MODIFIED="2010-09-06 15:30:42 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised double-blind placebo-controlled trial.</P>
<P>Single-centred with 3 parallel groups; follow-up for 8 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-06 15:31:20 +0100" MODIFIED_BY="[Empty name]">
<P>Location: South America.</P>
<P>Inclusion criteria: Pain and tenderness of the masticatory muscles. Clicking of the temporomandibular joint.</P>
<P>32 participants in the first intervention group (5 mg prazepam), 27 participants in the second intervention group (10 mg prazepam) and 24 participants in the control group (placebo).</P>
<P>Sex: 10 male (12%); 73 female (88%).</P>
<P>Age: 19 to 65 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-06 15:31:36 +0100" MODIFIED_BY="[Empty name]">
<P>Oral prazepam (bendodiazepine) 5 mg twice daily for 8 days (n = 32), or 10 mg daily for 8 days (n = 27), or placebo (n = 24).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-06 15:32:07 +0100" MODIFIED_BY="[Empty name]">
<P>Spontaneous TMJ pain.</P>
<P>TMJ pain during mastication.</P>
<P>TMJ pain on external palpation.</P>
<P>A symptom scale (0 = absent, 1 = slight, 2 = moderate, 3 = intense) was used to assess the participants at baseline and at day 8. Improvements were reported as a decrease in pain intensity by 2 points on the scale over this period. Signs and symptoms initially assessed as slight were not considered in the analysis.</P>
<P>Adverse reactions were reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-16 05:18:27 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-06 15:33:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ta-and-Dionne-2004">
<CHAR_METHODS MODIFIED="2010-09-06 15:33:00 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised double-blind placebo-controlled trial.</P>
<P>Single-centred with 3 parallel groups; follow-up for 6 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-06 15:33:24 +0100" MODIFIED_BY="[Empty name]">
<P>Location: USA.</P>
<P>Inclusion criteria: Participants with TMJ disc displacement with reduction and arthralgia or painful disc displacement of the TMJ. Participants with joint pain were required to have self-report of at least 1 month of daily or almost-daily pain.</P>
<P>24 participants in the first intervention group (celecoxib), 22 participants in the second intervention group (naproxen) and 22 participants in the control group (placebo).</P>
<P>Sex (female/male): Celecoxib group (17/7), naproxen (16/6), placebo (13/9).</P>
<P>Age: 18 to 65 years (median age 31).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-06 15:33:33 +0100" MODIFIED_BY="[Empty name]">
<P>Oral celecoxib (COX-2 inhibitor) 100 mg twice daily for 6 weeks (n = 24), or oral naproxen (NSAID) 500 mg twice daily for 6 weeks (n = 22) or placebo twice daily for 6 weeks (n = 22).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-06 15:33:47 +0100" MODIFIED_BY="[Empty name]">
<P>VAS assessment of pain intensity at baseline and 6 weeks.</P>
<P>Adverse reactions were reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-15 04:56:58 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-06 15:35:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tchivileva-et-al-2010">
<CHAR_METHODS MODIFIED="2010-09-06 15:34:42 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled, 2-period cross-over pilot study.</P>
<P>Single-centred; follow-up for 1 week.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-06 15:35:06 +0100" MODIFIED_BY="[Empty name]">
<P>Location: USA.</P>
<P>Inclusion criteria: Participants were eligible for the study if they met Research Diagnostic Criteria for TMD. Only Caucasian patients were evaluated.</P>
<P>40 participants.</P>
<P>Sex: All females.</P>
<P>Age: 18 to 60 years (mean 35.4, standard error 1.7 years).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-06 15:35:28 +0100" MODIFIED_BY="[Empty name]">
<P>Arm 1: 1 week of 20 mg propranolol twice a day, followed by a 1-week washout period and then a 1-week placebo period.</P>
<P>Arm 2: 1 week of placebo, followed by a 1-week washout period, and then a week of 20 mg of propranolol twice a day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-06 15:35:44 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: The average weekly pain intensity (measured on 0-100 numerical rating scale).</P>
<P>Secondary outcomes:<BR/>-Pain duration: percentage of time during the waking day when participants experienced pain.<BR/>- A pain index: calculated as a product of pain intensity by pain duration.</P>
<P>Subgroup analysis: by COMT haplotypes coding for reduced enzyme activity.</P>
<P>Adverse events were reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-16 17:03:50 +0100" MODIFIED_BY="[Empty name]">
<P>The authors concluded that propranolol significantly reduced a composite pain index and increased the number of patients reporting a reduction in pain intensity but did not decrease other clinical and experimental pain ratings. COMT haplotypes may serve as genetic predictors of propranolol treatment outcome, identifying a subgroup of TMD patients who will benefit from propranolol therapy.</P>
<P>There was no pharmaceutical industry sponsorship but some authors declared conflict of interest due to involvement in a private genetics company.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-06 16:43:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Winocur-et-al-2000">
<CHAR_METHODS MODIFIED="2010-09-06 16:42:41 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised double-blind placebo-controlled trial.</P>
<P>Single-centred with 2 parallel groups; follow-up for 4 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-06 16:42:54 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Israel.</P>
<P>Inclusion criteria: Patients with TMJ pain for at least 3 months, pain in the joint area associated with function; presence of TMJ tenderness to palpation on the reported side.</P>
<P>17 participants in the intervention group with mean age 35.6 <U>+</U> 14.2 (capsaicin) and 13 participants in the control group with mean age 37.5 <U>+</U> 16.7 (placebo).</P>
<P>Sex: 6 male (20%); 24 female (80%).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-06 16:43:13 +0100" MODIFIED_BY="[Empty name]">
<P>0.025% capsaicin cream applied topically over the painful area 4 times daily for 4 weeks (n = 17) or placebo cream (n = 13).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-06 16:43:29 +0100" MODIFIED_BY="[Empty name]">
<P>VAS ratings of present pain at baseline and at 4 weeks.</P>
<P>Maximal pain at baseline and at 4 weeks.</P>
<P>Effect of pain on daily activity at baseline and at 4 weeks.</P>
<P>Adverse reactions were reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-15 03:24:50 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>mg = milligrams; TMD = temporomandibular disorders; TMJ = temporomandibular joint; VAS = visual analogue scale.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2010-09-06 17:11:34 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-07-16 06:18:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bjorne-and-Agerberg-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-16 06:18:04 +0100" MODIFIED_BY="[Empty name]">
<P>Not a randomised controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-16 06:18:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dao-et-al-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-16 06:18:07 +0100" MODIFIED_BY="[Empty name]">
<P>Cross-over study with pooled analysis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-16 06:18:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-DeNucci-et-al-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-16 06:18:14 +0100" MODIFIED_BY="[Empty name]">
<P>Cross-over study with pooled analysis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-16 06:23:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Di-Rienzo-Businco-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-16 06:23:03 +0100" MODIFIED_BY="[Empty name]">
<P>No placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-06 17:10:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Epstein-et-al-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-06 17:10:44 +0100" MODIFIED_BY="[Empty name]">
<P>Not a randomised controlled trial.<BR/>Not clear TMD.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-14 23:17:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Feinmann-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-14 23:17:37 +0000" MODIFIED_BY="[Empty name]">
<P>Not TMD.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-06 17:10:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Franks-1965">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-06 17:10:46 +0100" MODIFIED_BY="[Empty name]">
<P>Age range of participants unclear.<BR/>Inclusion criteria unclear.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-06 17:10:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gallardo-et-al-1975">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-06 17:10:49 +0100" MODIFIED_BY="[Empty name]">
<P>Participants below 18 years old included in study.<BR/>Insufficient reporting.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-06 17:10:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gaudet-and-Brown-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-06 17:10:51 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective study, not a randomised controlled trial.<BR/>No pharmacological intervention.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-15 05:56:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gerschman-et-al-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-15 05:56:36 +0100" MODIFIED_BY="[Empty name]">
<P>Cross-over study with pooled analysis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-06 17:10:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gessel-1975">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-06 17:10:54 +0100" MODIFIED_BY="[Empty name]">
<P>Intervention was not a pharmacological agent.<BR/>Not a randomised controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-14 23:20:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Greene-and-Laskin-1971">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-14 23:20:33 +0000" MODIFIED_BY="[Empty name]">
<P>Age and sex distribution of participants were not stated.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-16 06:19:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Greene-and-Laskin-1974">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-16 06:19:52 +0100" MODIFIED_BY="[Empty name]">
<P>Not a randomised controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-06 17:10:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hodosh-et-al-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-06 17:10:57 +0100" MODIFIED_BY="[Empty name]">
<P>Not randomised.<BR/>No placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-06 17:10:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jagger-1973">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-06 17:10:59 +0100" MODIFIED_BY="[Empty name]">
<P>Participants below 18 years old included in the study.<BR/>Unclear duration of participants' pain.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-15 05:56:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lipp-et-al-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-15 05:56:14 +0100" MODIFIED_BY="[Empty name]">
<P>Pharmacological agent was injected.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-16 06:17:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Martani-et-al-1968">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-16 06:17:31 +0100" MODIFIED_BY="[Empty name]">
<P>Pharmacological agent was injected.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-15 05:50:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mejersjo-Wenneberg-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-15 05:50:42 +0100" MODIFIED_BY="[Empty name]">
<P>No placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-15 05:50:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Minakuchi-et-al-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-15 05:50:40 +0100" MODIFIED_BY="[Empty name]">
<P>No placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-16 06:22:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mongini-et-al-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-16 06:22:42 +0100" MODIFIED_BY="[Empty name]">
<P>Not clear TMD.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-06 16:45:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Murakami-et-al-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-06 16:45:04 +0100" MODIFIED_BY="[Empty name]">
<P>Not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-16 06:20:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nekora_x002d_Azak-et-al-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-16 06:20:53 +0100" MODIFIED_BY="[Empty name]">
<P>Not a randomised controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-16 06:18:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nemcovsky-et-al-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-16 06:18:29 +0100" MODIFIED_BY="[Empty name]">
<P>No placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-06 17:11:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Plesh-et-al-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-06 17:11:05 +0100" MODIFIED_BY="[Empty name]">
<P>No placebo group.<BR/>Not clear TMD.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-06 17:11:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rizzatti_x002d_Barbosa-2003a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-06 17:11:12 +0100" MODIFIED_BY="[Empty name]">
<P>Age group unclear.<BR/>Inclusion criteria unclear.<BR/>Insufficient reporting.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-16 06:22:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rizzatti_x002d_Barbosa-2003b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-16 06:22:05 +0100" MODIFIED_BY="[Empty name]">
<P>No clear control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-06 17:11:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schwartz-et-al-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-06 17:11:16 +0100" MODIFIED_BY="[Empty name]">
<P>Pharmacological agent was injected.<BR/>Not clear TMD.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-16 06:22:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shankland-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-16 06:22:25 +0100" MODIFIED_BY="[Empty name]">
<P>Not a randomised controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-06 17:11:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shiffman-et-al-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-06 17:11:24 +0100" MODIFIED_BY="[Empty name]">
<P>Age group unclear.<BR/>Duration of participants' pain less than 3 months.<BR/>Duration of study unclear.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-06 16:45:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shin-and-Choi-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-06 16:45:20 +0100" MODIFIED_BY="[Empty name]">
<P>Participants below 18 years old included in the study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-16 06:24:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Singer-and-Dionne-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-16 06:24:00 +0100" MODIFIED_BY="[Empty name]">
<P>Not clear TMD.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-06 17:11:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stiesch_x002d_Scholz-et-al-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-06 17:11:27 +0100" MODIFIED_BY="[Empty name]">
<P>Intervention was not a pharmacological agent.<BR/>Not a randomised controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-06 17:11:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thie-et-al-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-06 17:11:30 +0100" MODIFIED_BY="[Empty name]">
<P>Not TMD.<BR/>No placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-06 17:11:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tversky-et-al-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-06 17:11:32 +0100" MODIFIED_BY="[Empty name]">
<P>Participants below 18 years old included in study.<BR/>No placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-06 17:11:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-van-der-Berghe-et-al-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-06 17:11:34 +0100" MODIFIED_BY="[Empty name]">
<P>No randomisation.<BR/>Participants below 18 years old included in study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-16 06:16:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Volinier-and-Bianchi-1967">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-16 06:16:39 +0100" MODIFIED_BY="[Empty name]">
<P>Pharmacological agent was injected.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-16 06:16:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zander-et-al-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-16 06:16:56 +0100" MODIFIED_BY="[Empty name]">
<P>Not a randomised controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>TMD = temporomandibular disorders.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-09-06 16:43:51 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2010-09-06 16:43:40 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-06 15:20:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ekberg-et-al-1996">
<DESCRIPTION>
<P>Quote: "... the patients were allocated at random ...".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-06 15:22:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Harkins-et-al-1991">
<DESCRIPTION>
<P>Quote: "Ten patients were randomly assigned to each group...".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-06 15:24:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Herman-et-al-2002">
<DESCRIPTION>
<P>Quote: "Subjects were allocated to their treatment group by means of a randomised block design with the blocking variable being the current use of psychotropic medications".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-17 18:36:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kimos-et-al-2007">
<DESCRIPTION>
<P>Quote: "A computer-generated randomization code list was utilized to randomly allocate patients in two study groups".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-06 15:27:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lobo-et-al-2004">
<DESCRIPTION>
<P>Quote: "Allocation ... was accomplished by blind selection from a pool of 52 numbers (26 experimental and 26 control) in a box. Once the number was chosen, it was not returned to the box".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-17 18:47:16 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nguyen-et-al-2001">
<DESCRIPTION>
<P>Quote: "The randomization order was obtained through a computer-generated simple consecutive randomization. The assignment procedure ensured having an equal number of subjects in each of the active medication group and the inactive medication group...".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-06 15:30:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Roldan-et-al-1990">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-06 15:32:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rossi-et-al-1983">
<DESCRIPTION>
<P>Quote: "... the patients were randomly assigned to one of three possible treatments...".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-18 10:14:01 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ta-and-Dionne-2004">
<DESCRIPTION>
<P>Quote: "Subjects ... were randomly assigned...; Treatment randomization was stratified using a block size of 9 or 6 by National Institutes of Health Pharmaceutical Development Service".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-06 15:35:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tchivileva-et-al-2010">
<DESCRIPTION>
<P>Quote: "... participants were randomly allocated in blocks of eight...".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-06 16:43:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Winocur-et-al-2000">
<DESCRIPTION>
<P>Quote: "Patients were randomly divided into 2 groups".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-09-06 16:43:40 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-06 15:20:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ekberg-et-al-1996">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-06 15:22:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Harkins-et-al-1991">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-06 15:24:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Herman-et-al-2002">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-06 15:26:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kimos-et-al-2007">
<DESCRIPTION>
<P>Quote: "... concealed randomization and the according allocation were implemented by a research assistant. Neither the patients nor the main investigator was aware of the random group allocation".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-06 15:27:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lobo-et-al-2004">
<DESCRIPTION>
<P>Quote: "A Gelb Center employee not on the research team performed selection. Numbers assigned to each subject were monitored by the employee and were not disclosed until the study was completed".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-06 15:29:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nguyen-et-al-2001">
<DESCRIPTION>
<P>Quote: "A copy of the randomisation code was maintained in the custody of a neutral party until completion of the clinical portion of the study and until all the data was collected".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-18 09:30:37 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Roldan-et-al-1990">
<DESCRIPTION>
<P>Glass jars numbered according to key.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-06 15:32:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rossi-et-al-1983">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-18 10:17:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ta-and-Dionne-2004">
<DESCRIPTION>
<P>Assumed done because randomisation was done independently. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-06 15:36:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tchivileva-et-al-2010">
<DESCRIPTION>
<P>Quote: "The Investigational Drug Service at the UNC Hospitals performed the randomization and kept the master list of assignments".</P>
<P>Likely to be adequate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-06 16:43:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Winocur-et-al-2000">
<DESCRIPTION>
<P>Probably done by RAFA laboratories.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2010-09-06 16:43:43 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-18 09:02:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ekberg-et-al-1996">
<DESCRIPTION>
<P>Quote: "... both the investigator and patient were blind to the kind of treatment".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-06 15:22:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Harkins-et-al-1991">
<DESCRIPTION>
<P>Quote: "... double-blind placebo-controlled trial...".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-18 09:07:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Herman-et-al-2002">
<DESCRIPTION>
<P>Quote: "The study design was a double-blind, placebo-controlled ... The capsules were formulated to have the same appearance...".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-06 15:26:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kimos-et-al-2007">
<DESCRIPTION>
<P>Quote: "For double-blinding purposes the active and placebo medications were packed in identical looking capsules. ...neither the investigator nor the patients were aware of the medication codes".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-18 09:18:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lobo-et-al-2004">
<DESCRIPTION>
<P>Quote: "The study was conducted in a randomised double-blind fashion".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-06 15:29:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nguyen-et-al-2001">
<DESCRIPTION>
<P>Quote: "... (placebo) group took identical-looking tablets...The supplier provided study medications and the placebo preparations in identical bottles. Investigators and subjects were blinded to the contents of the assigned medications throughout the study. ... the clinician was blinded to whether the subject was in the active or inactive medication group".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-18 09:26:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Roldan-et-al-1990">
<DESCRIPTION>
<P>Double-blind. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-06 15:32:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rossi-et-al-1983">
<DESCRIPTION>
<P>Quote: "... a double-blind design ... identically appearing tablets... ; ... evaluation ... was made by the same clinician who made the initial assessment of the patient and who was unaware of the treatment received by the patients".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-06 15:33:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ta-and-Dionne-2004">
<DESCRIPTION>
<P>Quote: "... double-blind, placebo-controlled trial...".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-06 15:36:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tchivileva-et-al-2010">
<DESCRIPTION>
<P>Quote: "The treatment sequence code for each participant was not disclosed to the project investigators till completion of the entire research protocol.... Placebo pills were identical to the propranolol pills to ensure participant and investigator blinding".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-06 16:43:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Winocur-et-al-2000">
<DESCRIPTION>
<P>Quote: "All tubes were prepared by RAFA laboratories and appeared completely identical. The study was conducted in a randomised, double-blind fashion. Neither the patient nor the examiner was aware of the tube contents. Patients were informed ... that both creams might or might not cause a warm, stinging or burning sensation when applied to the area".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2010-09-06 16:43:46 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-09-06 15:20:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ekberg-et-al-1996">
<DESCRIPTION>
<P>Originally 39 patients were randomised (21 diclofenac and 18 placebo). 7 patients (5 diclofenac and 2 placebo) withdrew from the study for different reasons (some of them did not want to take oral medication or had upper respiratory infections).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-09-06 15:22:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Harkins-et-al-1991">
<DESCRIPTION>
<P>1 participant (clonazepam group) dropped out after 1 week because of migraine. Study was deigned to assess outcome at 60 days but due to high drop-out rate only 30 days results are presented.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-09-06 15:24:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Herman-et-al-2002">
<DESCRIPTION>
<P>Quote: "... no subject drop outs or withdrawals".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-09-06 15:26:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kimos-et-al-2007">
<DESCRIPTION>
<P>States number and reasons for withdrawals on a special figure (total 28% drop-out rate at week 12). Follow-up for intention-to-treat analysis where possible.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-18 10:45:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lobo-et-al-2004">
<DESCRIPTION>
<P>There seem to be no withdrawals.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-09-06 15:29:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nguyen-et-al-2001">
<DESCRIPTION>
<P>States numbers and reasons for withdrawals in a special table (Table 4). Quote: "Although nine subjects dropped out of the active medication group, in three of these the reason for dropping out could be directly attributed to the study medications...".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-09-06 15:30:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Roldan-et-al-1990">
<DESCRIPTION>
<P>41 out of 60 completed the study (31.7% drop-out rate). The reasons for withdrawals are not clear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-09-06 15:32:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rossi-et-al-1983">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-09-06 15:33:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ta-and-Dionne-2004">
<DESCRIPTION>
<P>Quote: "...78 subjects were recruited and with a total 68 subjects completing the study".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-09-06 15:36:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tchivileva-et-al-2010">
<DESCRIPTION>
<P>1 drop out in each arm; reasons for missing outcome data unlikely to be related to true outcome; missing outcome data are balanced across treatment arms; intention-to-treat analysis is reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-09-06 16:43:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Winocur-et-al-2000">
<DESCRIPTION>
<P>Withdrawals are not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2010-09-06 15:34:00 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-18 11:57:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ekberg-et-al-1996">
<DESCRIPTION>
<P>Results for the main outcome are presented, together with the results of clinical examination.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-06 15:22:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Harkins-et-al-1991">
<DESCRIPTION>
<P>Both VAS-observer and VAS-patient pain levels are reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-18 11:26:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Herman-et-al-2002">
<DESCRIPTION>
<P>Both primary and secondary outcomes are reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-06 15:26:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kimos-et-al-2007">
<DESCRIPTION>
<P>All 3 proposed outcomes are reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-18 11:30:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lobo-et-al-2004">
<DESCRIPTION>
<P>Results for Numerical Graphic Rating scale (NGRS) are reported as outlined in the Methods section.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-06 15:29:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nguyen-et-al-2001">
<DESCRIPTION>
<P>All stated outcomes seem to be reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-06 15:30:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Roldan-et-al-1990">
<DESCRIPTION>
<P>Helkimo Dysfunction index.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-18 11:46:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rossi-et-al-1983">
<DESCRIPTION>
<P>All outcomes are reported in tables.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-06 15:34:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ta-and-Dionne-2004">
<DESCRIPTION>
<P>Both primary and secondary outcomes are reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-16 17:39:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tchivileva-et-al-2010">
<DESCRIPTION>
<P>It is clear that the paper reports all expected outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-18 11:49:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Winocur-et-al-2000">
<DESCRIPTION>
<P>All stated outcomes are reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2010-09-06 16:43:51 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-06 15:20:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ekberg-et-al-1996">
<DESCRIPTION>
<P>No evidence of baseline imbalance. Rescue analgesic was used by 12 patients in diclofenac group and 7 in placebo, but unlikely to cause bias. Pharmaceutical industry sponsorship unlikely to bias the results as the study was conducted at Lund University and there was no difference between groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-06 15:22:40 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Harkins-et-al-1991">
<DESCRIPTION>
<P>Interim results are reported at 30-day follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-18 12:22:07 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Herman-et-al-2002">
<DESCRIPTION>
<P>There was some baseline imbalance between groups. Not clear if randomised block design could lead to guessing the intervention group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-18 12:16:11 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kimos-et-al-2007">
<DESCRIPTION>
<P>Patients were taking other medications that could not be stopped.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-18 12:20:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lobo-et-al-2004">
<DESCRIPTION>
<P>Small baseline imbalance. Not clear if other medications were used. Pharmaceutical industry sponsorship.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-06 15:29:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nguyen-et-al-2001">
<DESCRIPTION>
<P>No evidence of baseline imbalance. Quote: "The subjects were told not to take ant anti-inflammatory drugs for the remainder of the study". Additional treatments were administered either before or after the study. Not clear if paracetamol was allowed as a rescue medication.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-18 12:35:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Roldan-et-al-1990">
<DESCRIPTION>
<P>No enough information to make judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-18 12:38:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rossi-et-al-1983">
<DESCRIPTION>
<P>No enough information to make judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-06 15:34:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ta-and-Dionne-2004">
<DESCRIPTION>
<P>Quote: "All subjects were evaluated by an investigator who is a dentist trained in orofacial pain. Use of anti-coagulants, NSAIDs (including low-dose aspirin) other than the study drug, muscle relaxants or chronic use of an analgesic or anti-ulcer drug was prohibited during the study". No evidence of baseline imbalance.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-06 16:42:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tchivileva-et-al-2010">
<DESCRIPTION>
<P>Quote: "A possible carryover effect was assessed by independent t-test, and no statistically significant carryover effect was observed for any study outcome (data not shown)".</P>
<P>Quote: "Patients taking the following medications were also excluded: drugs with central nervous system activity and b-blockers. The use of selective serotonin re-uptake inhibitors was permitted only if the participant had already been taking it for at least 1 month before study enrolment. Abortive medications for headaches and NSAIDs were not allowed during the last 2 days before the study visits".</P>
<P>Study did not report pairwise differences between treatment arms.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-06 16:43:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Winocur-et-al-2000">
<DESCRIPTION>
<P>Quote: "All patients were examined by 1 experienced clinician...". No evidence of baseline imbalance. No information on rescue medication.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2010-02-17 19:21:30 +0000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Clear description of inclusion/exclusion criteria?</NAME>
<DESCRIPTION>
<P>Was there a clear description of the inclusion and exclusion criteria?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2010-02-17 19:21:30 +0000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Intention to treat analysis?</NAME>
<DESCRIPTION>
<P>Was an intention to treat analysis carried out?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.03" NO="3">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2010-02-17 19:21:30 +0000" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Could other treatments have biased the results?</NAME>
<DESCRIPTION>
<P>Could other treatments have biased the results?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2010-02-17 19:21:30 +0000" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Were withdrawals from the study accounted for?</NAME>
<DESCRIPTION>
<P>Were withdrawals from the study accounted for?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-11" LEVEL="STUDY" MODIFIED="2010-02-17 19:21:30 +0000" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Comparability of groups?</NAME>
<DESCRIPTION>
<P>Were the groups comparable at baseline?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-12" LEVEL="STUDY" MODIFIED="2010-02-17 17:12:52 +0000" MODIFIED_BY="[Empty name]" NO="12">
<NAME>Pharmaceutical industry sponsorship</NAME>
<DESCRIPTION>
<P>Was the study sponsored by a pharmaceutical company?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2010-09-06 16:51:06 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2010-09-06 16:51:06 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-09-06 16:46:17 +0100" MODIFIED_BY="[Empty name]">Drug doses by study and by recommended daily dose</TITLE>
<TABLE COLS="6" ROWS="12">
<TR>
<TD>
<P>
<B>Study</B>
</P>
</TD>
<TD>
<P>
<B>Drug 1</B>
</P>
</TD>
<TD>
<P>
<B>Recommended daily dose</B>
</P>
</TD>
<TD>
<P>
<B>Drug 2</B>
</P>
</TD>
<TD>
<P>
<B>Recommended daily dose</B>
</P>
</TD>
<TD>
<P>
<B>Drug 3</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ekberg-et-al-1996" TYPE="STUDY">Ekberg et al 1996</LINK> </P>
</TD>
<TD>
<P>Diclofenac 50 mg 3 times a day (100% MDD)</P>
</TD>
<TD>
<P>150 mg daily</P>
</TD>
<TD>
<P>Diclofenac 50 mg twice daily (66% MDD)</P>
</TD>
<TD>
<P>150 mg daily</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Harkins-et-al-1991" TYPE="STUDY">Harkins et al 1991</LINK>
</P>
</TD>
<TD>
<P>Clonazepam 0.25-1 mg daily, therefore dose used in this study was much lower than therapeutic dose for management of epilepsy</P>
</TD>
<TD>
<P>Maintenance dose for epilepsy is 4-8 mg</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P> -</P>
</TD>
<TD>
<P> -</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Herman-et-al-2002" TYPE="STUDY">Herman et al 2002</LINK>
</P>
</TD>
<TD>
<P>Clonazepam 0.5 mg daily, therefore dose used in this study was much lower than therapeutic dose for management of epilepsy</P>
</TD>
<TD>
<P>Maintenance dose for epilepsy is 4-8 mg</P>
</TD>
<TD>
<P>Cyclobenzaprine 10 mg daily (30% MDD)</P>
</TD>
<TD>
<P>Maximum dose of 30 mg daily (usually for 2-3 weeks maximum)</P>
</TD>
<TD>
<P>Placebo</P>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kimos-et-al-2007" TYPE="STUDY">Kimos et al 2007</LINK>
</P>
</TD>
<TD>
<P>Gabapentin 300 mg to 4200 mg daily (16.7%-233% MDD)</P>
</TD>
<TD>
<P>Maximum 1.8 g daily for neuropathic pain</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P> -</P>
</TD>
<TD>
<P> -</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Lobo-et-al-2004" TYPE="STUDY">Lobo et al 2004</LINK>
</P>
</TD>
<TD>
<P>Theraflex-TMJ twice daily</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P> -</P>
</TD>
<TD>
<P> -</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Nguyen-et-al-2001" TYPE="STUDY">Nguyen et al 2001</LINK>
</P>
</TD>
<TD>
<P>Glucosamine/chondroitin 750 mg/600 mg twice daily</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P> -</P>
</TD>
<TD>
<P> -</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Roldan-et-al-1990" TYPE="STUDY">Roldan et al 1990</LINK>
</P>
</TD>
<TD>
<P>Piroxicam 20 mg daily (100% MDD)</P>
</TD>
<TD>
<P>20 mg</P>
</TD>
<TD>
<P>Diazepam 2 mg daily  (13.3%-100% MDD)</P>
</TD>
<TD>
<P>2-15 mg daily for muscle spasm</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Rossi-et-al-1983" TYPE="STUDY">Rossi et al 1983</LINK>
</P>
</TD>
<TD>
<P>Prazepam 5 mg twice daily (16.7%-33.3% MDD)</P>
</TD>
<TD>
<P>30-60 mg for anxiety</P>
</TD>
<TD>
<P>Prazepam 10 mg twice daily (33.3%-66.7% MDD)</P>
</TD>
<TD>
<P>30-60 mg for anxiety</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ta-and-Dionne-2004" TYPE="STUDY">Ta and Dionne 2004</LINK>
</P>
</TD>
<TD>
<P>Celecoxib 100 mg twice daily (50%-100% MDD)</P>
</TD>
<TD>
<P>200 mg (osteoarthritis)</P>
<P>40 mg (rheumatoid arthritis)</P>
</TD>
<TD>
<P>Naproxen 500 mg twice daily (66.6%-100% MDD)</P>
</TD>
<TD>
<P>1 g (or 1.5 g in the USA)</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Tchivileva-et-al-2010" TYPE="STUDY">Tchivileva et al 2010</LINK>
</P>
</TD>
<TD>
<P>Propranolol 20 mg twice daily (no recognised dose for analgesic effect) </P>
</TD>
<TD>
<P>Not applicable</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Winocur-et-al-2000" TYPE="STUDY">Winocur et al 2000</LINK>
</P>
</TD>
<TD>
<P>Capsaicin 0.025% 4 times a day</P>
</TD>
<TD>
<P>Apply 3-4 times daily (different strengths of cream available)</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P> -</P>
</TD>
<TD>
<P> -</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Drug doses source: Martindale: The Complete Drug Reference. Martindale 3<SUP>rd</SUP> quarter 2010 update. Accessed via <A HREF="http://www.medicinescomplete.com/">www.medicinescomplete.com</A> on 1st July 2010; MDD = maximum daily dose.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2010-09-07 12:12:46 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2010-08-16 13:03:17 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Comparison of oral benzodiazepine (clonazepam) versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2010-08-16 13:03:17 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="53" TOTAL_2="55" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Pain</NAME>
<GROUP_LABEL_1>Favours experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.01.01" MODIFIED="2009-07-16 15:06:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Visual analogue scale assessment of pain on palpation of the right masseter muscle</NAME>
<CONT_DATA CI_END="0.43577676300944357" CI_START="-2.6557767630094435" EFFECT_SIZE="-1.1099999999999999" ESTIMABLE="YES" MEAN_1="1.27" MEAN_2="2.38" MODIFIED="2009-07-16 15:06:32 +0100" MODIFIED_BY="[Empty name]" ORDER="20" SD_1="1.49" SD_2="2.0" SE="0.7886761058888496" STUDY_ID="STD-Harkins-et-al-1991" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.01.02" MODIFIED="2009-07-16 15:08:14 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Visual analogue scale assessment of pain on palpation of the left masseter muscle</NAME>
<CONT_DATA CI_END="0.6761694355266357" CI_START="-2.4561694355266352" EFFECT_SIZE="-0.8899999999999999" ESTIMABLE="YES" MEAN_1="1.36" MEAN_2="2.25" MODIFIED="2009-07-16 15:08:14 +0100" MODIFIED_BY="[Empty name]" ORDER="21" SD_1="1.57" SD_2="1.98" SE="0.7990807218297786" STUDY_ID="STD-Harkins-et-al-1991" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.01.03" MODIFIED="2009-07-16 15:14:00 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Participants' assessment of improvement of pain levels in right TMJ</NAME>
<CONT_DATA CI_END="1.6579660744282503" CI_START="-3.13796607442825" EFFECT_SIZE="-0.7399999999999998" ESTIMABLE="YES" MEAN_1="2.64" MEAN_2="3.38" MODIFIED="2009-07-16 15:14:00 +0100" MODIFIED_BY="[Empty name]" ORDER="23" SD_1="2.8" SD_2="2.67" SE="1.2234745604220794" STUDY_ID="STD-Harkins-et-al-1991" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.01.04" MODIFIED="2009-07-16 15:15:20 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Participants' assessment of improvement of pain levels in left TMJ</NAME>
<CONT_DATA CI_END="0.9646941053697162" CI_START="-3.684694105369716" EFFECT_SIZE="-1.3599999999999999" ESTIMABLE="YES" MEAN_1="2.64" MEAN_2="4.0" MODIFIED="2009-07-16 15:15:20 +0100" MODIFIED_BY="[Empty name]" ORDER="24" SD_1="2.84" SD_2="2.45" SE="1.1860902157930484" STUDY_ID="STD-Harkins-et-al-1991" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.01.05" MODIFIED="2010-06-25 15:56:45 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Visual analogue scale assessment of jaw pain</NAME>
<CONT_DATA CI_END="1.292532116983119" CI_START="-1.6925321169831193" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="2.8" MEAN_2="3.0" MODIFIED="2010-06-25 15:56:45 +0100" MODIFIED_BY="[Empty name]" ORDER="25" SD_1="2.1" SD_2="1.9" SE="0.7615099709770292" STUDY_ID="STD-Herman-et-al-2002" TOTAL_1="13" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2010-09-06 17:15:09 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Comparison of oral anticonvulsant (gabapentin) versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2010-08-16 13:04:19 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="72" TOTAL_2="60" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Pain</NAME>
<GROUP_LABEL_1>Gabapentin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.01.01" MODIFIED="2009-07-16 16:17:39 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Visual analogue scale assessment of spontaneous pain in the TMJ</NAME>
<CONT_DATA CI_END="-1.6939076362684395" CI_START="-4.70609236373156" EFFECT_SIZE="-3.2" ESTIMABLE="YES" MEAN_1="2.2" MEAN_2="5.4" MODIFIED="2009-07-16 16:17:39 +0100" MODIFIED_BY="[Empty name]" ORDER="33" SD_1="2.37" SD_2="2.67" SE="0.7684285913473028" STUDY_ID="STD-Kimos-et-al-2007" TOTAL_1="24" TOTAL_2="20" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.01.02" MODIFIED="2009-07-16 16:24:50 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Palpation index: Number of tender sites in the masticatory muscles</NAME>
<CONT_DATA CI_END="-2.129479358689593" CI_START="-6.990520641310406" EFFECT_SIZE="-4.56" ESTIMABLE="YES" MEAN_1="3.04" MEAN_2="7.6" MODIFIED="2009-07-16 16:24:50 +0100" MODIFIED_BY="[Empty name]" ORDER="34" SD_1="3.85" SD_2="4.29" SE="1.2400843385297093" STUDY_ID="STD-Kimos-et-al-2007" TOTAL_1="24" TOTAL_2="20" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.01.03" MODIFIED="2009-07-16 16:28:11 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Visual analogue scale assessment of patients assessment of global function at the end of the study</NAME>
<CONT_DATA CI_END="0.09673523617159385" CI_START="-3.096735236171594" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="3.5" MODIFIED="2009-07-16 16:28:11 +0100" MODIFIED_BY="[Empty name]" ORDER="35" SD_1="2.5" SD_2="2.84" SE="0.8146758046405126" STUDY_ID="STD-Kimos-et-al-2007" TOTAL_1="24" TOTAL_2="20" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2010-09-06 17:15:56 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Comparison of topical capsaicin versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.01" MODIFIED="2010-09-06 17:15:56 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="51" TOTAL_2="39" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Pain</NAME>
<GROUP_LABEL_1>Topical capsaicin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.01.01" MODIFIED="2009-07-16 17:06:36 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>Visual analogue scale assessment of present pain</NAME>
<CONT_DATA CI_END="1.2333640661627032" CI_START="-2.453364066162703" EFFECT_SIZE="-0.6099999999999999" ESTIMABLE="YES" MEAN_1="3.39" MEAN_2="4.0" MODIFIED="2009-07-16 17:06:36 +0100" MODIFIED_BY="[Empty name]" ORDER="39" SD_1="2.62" SD_2="2.5" SE="0.9405091525675592" STUDY_ID="STD-Winocur-et-al-2000" TOTAL_1="17" TOTAL_2="13" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.01.02" MODIFIED="2009-07-16 17:08:27 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>Visual analogue scale assessment of maximum pain whilst using medication</NAME>
<CONT_DATA CI_END="1.0685627984018544" CI_START="-2.8885627984018547" EFFECT_SIZE="-0.9100000000000001" ESTIMABLE="YES" MEAN_1="4.82" MEAN_2="5.73" MODIFIED="2009-07-16 17:08:27 +0100" MODIFIED_BY="[Empty name]" ORDER="40" SD_1="2.97" SD_2="2.55" SE="1.0094893651151273" STUDY_ID="STD-Winocur-et-al-2000" TOTAL_1="17" TOTAL_2="13" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.01.03" MODIFIED="2009-07-16 17:09:54 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>Visual analogue scale of effect of pain on daily activity</NAME>
<CONT_DATA CI_END="0.8818924132216104" CI_START="-3.1218924132216106" EFFECT_SIZE="-1.12" ESTIMABLE="YES" MEAN_1="2.11" MEAN_2="3.23" MODIFIED="2009-07-16 17:09:54 +0100" MODIFIED_BY="[Empty name]" ORDER="41" SD_1="2.49" SD_2="2.97" SE="1.0213924485410355" STUDY_ID="STD-Winocur-et-al-2000" TOTAL_1="17" TOTAL_2="13" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2010-09-06 14:59:37 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Comparison of oral NSAID (diclofenac) versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="21" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-09-06 14:59:37 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="48" TOTAL_2="48" WEIGHT="0.0" Z="0.0">
<NAME>Pain</NAME>
<GROUP_LABEL_1>Favours experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="8" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-09-06 14:59:37 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>Severe or very severe symptoms</NAME>
<DICH_DATA CI_END="1.8354053603053626" CI_START="0.4171421837150025" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.26373199572815714" LOG_CI_START="-0.3797158896835307" LOG_EFFECT_SIZE="-0.057991946977686754" MODIFIED="2009-12-23 16:21:44 +0000" MODIFIED_BY="[Empty name]" ORDER="8" O_E="0.0" SE="0.3779644730092272" STUDY_ID="STD-Ekberg-et-al-1996" TOTAL_1="16" TOTAL_2="16" VAR="0.14285714285714285" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="9" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-09-06 14:59:37 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>Pain at rest (not improved)</NAME>
<DICH_DATA CI_END="1.7083675962960143" CI_START="0.462502015668773" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.23258132529090397" LOG_CI_START="-0.33488637018566664" LOG_EFFECT_SIZE="-0.05115252244738131" MODIFIED="2009-12-23 16:18:53 +0000" MODIFIED_BY="[Empty name]" ORDER="35" O_E="0.0" SE="0.3333333333333333" STUDY_ID="STD-Ekberg-et-al-1996" TOTAL_1="16" TOTAL_2="16" VAR="0.1111111111111111" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="8" I2="0.0" ID="CMP-004.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-09-06 14:59:37 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>Tenderness on palpation of three or more masticatory muscles</NAME>
<DICH_DATA CI_END="1.6694093372690153" CI_START="0.3369455216539001" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.22256283824936696" LOG_CI_START="-0.47244031146596677" LOG_EFFECT_SIZE="-0.12493873660829993" MODIFIED="2009-12-23 16:12:25 +0000" MODIFIED_BY="[Empty name]" ORDER="33" O_E="0.0" SE="0.40824829046386296" STUDY_ID="STD-Ekberg-et-al-1996" TOTAL_1="16" TOTAL_2="16" VAR="0.16666666666666663" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2010-08-16 13:04:49 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Comparison of oral NSAID (naproxen) versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.01" MODIFIED="2010-08-16 13:04:49 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="22" TOTAL_2="22" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Pain</NAME>
<GROUP_LABEL_1>Oral naproxen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.01.01" MODIFIED="2010-06-25 15:59:24 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>Visual analogue scale assessment of pain intensity</NAME>
<CONT_DATA CI_END="-1.2493909213151246" CI_START="-2.1406090786848755" EFFECT_SIZE="-1.695" ESTIMABLE="YES" MEAN_1="1.171" MEAN_2="2.866" MODIFIED="2010-06-25 15:59:24 +0100" MODIFIED_BY="[Empty name]" ORDER="13" SD_1="0.745" SD_2="0.763" SE="0.2273557484728204" STUDY_ID="STD-Ta-and-Dionne-2004" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2010-08-16 13:04:59 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Comparison of oral COX-2 inhibitor (celecoxib) versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-006.01" MODIFIED="2010-08-16 13:04:59 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="24" TOTAL_2="22" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Pain</NAME>
<GROUP_LABEL_1>Celecoxib</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.01.01" MODIFIED="2010-06-25 16:00:16 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>Visual analogue scale assessment of pain intensity</NAME>
<CONT_DATA CI_END="0.4538124556073115" CI_START="-0.4018124556073119" EFFECT_SIZE="0.0259999999999998" ESTIMABLE="YES" MEAN_1="2.892" MEAN_2="2.866" MODIFIED="2010-06-25 16:00:16 +0100" MODIFIED_BY="[Empty name]" ORDER="18" SD_1="0.713" SD_2="0.763" SE="0.21827567189083152" STUDY_ID="STD-Ta-and-Dionne-2004" TOTAL_1="24" TOTAL_2="22" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2010-08-16 13:05:11 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Comparison of topical methyl salicylate versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-007.01" MODIFIED="2010-08-16 13:05:11 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="26" TOTAL_2="26" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Pain</NAME>
<GROUP_LABEL_1>Topical methyl salicylate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.01.01" MODIFIED="2009-07-18 04:42:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Numerical graph rating scale assessment of spontaneous TMJ pain</NAME>
<CONT_DATA CI_END="-0.4493909258955597" CI_START="-1.35060907410444" EFFECT_SIZE="-0.8999999999999999" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="3.4" MODIFIED="2009-07-16 14:27:36 +0100" MODIFIED_BY="[Empty name]" ORDER="16" SD_1="0.7" SD_2="0.5" SE="0.229906813420444" STUDY_ID="STD-Lobo-et-al-2004" TOTAL_1="14" TOTAL_2="14" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.01.02" MODIFIED="2009-07-18 04:42:48 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Numerical graph rating scale assessment of spontaneous masseter muscle pain</NAME>
<CONT_DATA CI_END="-1.6194017739176814" CI_START="-2.3805982260823186" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="3.5" MODIFIED="2009-07-16 14:30:10 +0100" MODIFIED_BY="[Empty name]" ORDER="17" SD_1="0.5" SD_2="0.45" SE="0.1941863366288507" STUDY_ID="STD-Lobo-et-al-2004" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2010-08-16 13:05:24 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Comparison of oral muscle relaxant (cyclobenzaprine) versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-008.01" MODIFIED="2010-08-16 13:05:24 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="13" TOTAL_2="15" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Pain</NAME>
<GROUP_LABEL_1>Oral cyclobenzaprine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-008.01.01" MODIFIED="2010-06-25 16:00:57 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Visual analogue scale assessment of jaw pain</NAME>
<CONT_DATA CI_END="0.07183119455844156" CI_START="-2.6718311945584414" EFFECT_SIZE="-1.3" ESTIMABLE="YES" MEAN_1="1.7" MEAN_2="3.0" MODIFIED="2010-06-25 16:00:57 +0100" MODIFIED_BY="[Empty name]" ORDER="28" SD_1="1.8" SD_2="1.9" SE="0.6999267360927399" STUDY_ID="STD-Herman-et-al-2002" TOTAL_1="13" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2010-09-06 17:16:41 +0100" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Comparison of oral chondroitin-glucosamine versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-009.01" MODIFIED="2010-09-06 15:01:16 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="42" TOTAL_2="60" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Pain</NAME>
<GROUP_LABEL_1>Chondroitin-Glucosamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-009.01.01" MODIFIED="2010-06-25 16:01:22 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Visual analogue scale assessment of pain intensity</NAME>
<CONT_DATA CI_END="0.7613612538965748" CI_START="-2.161361253896575" EFFECT_SIZE="-0.7000000000000002" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="4.9" MODIFIED="2010-06-25 16:01:22 +0100" MODIFIED_BY="[Empty name]" ORDER="42" SD_1="2.4" SD_2="1.7" SE="0.7456061771663184" STUDY_ID="STD-Nguyen-et-al-2001" TOTAL_1="14" TOTAL_2="20" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-009.01.02" MODIFIED="2010-06-25 16:10:58 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Pain on TMJ palpation assessed on an ordinal scale</NAME>
<CONT_DATA CI_END="2.4910445550969196" CI_START="-3.091044555096919" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" MEAN_1="3.6" MEAN_2="3.9" MODIFIED="2009-07-16 17:29:15 +0100" MODIFIED_BY="[Empty name]" ORDER="44" SD_1="3.3" SD_2="5.0" SE="1.4240284908867318" STUDY_ID="STD-Nguyen-et-al-2001" TOTAL_1="14" TOTAL_2="20" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-009.01.03" MODIFIED="2010-09-06 15:01:16 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Total pain rating index assessed on McGill Pain Questionnaire</NAME>
<CONT_DATA CI_END="11.488776534520026" CI_START="-8.28877653452003" EFFECT_SIZE="1.5999999999999979" ESTIMABLE="YES" MEAN_1="25.4" MEAN_2="23.8" MODIFIED="2010-09-06 15:01:16 +0100" MODIFIED_BY="[Empty name]" ORDER="43" SD_1="15.0" SD_2="13.7" SE="5.045386860432862" STUDY_ID="STD-Nguyen-et-al-2001" TOTAL_1="14" TOTAL_2="20" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2010-09-07 12:09:43 +0100" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Comparison of oral NSAID (piroxicam) versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7607858693862741" CI_START="0.2897593003801683" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-010.01" LOG_CI_END="0.24570654427030766" LOG_CI_START="-0.5379626156267836" LOG_EFFECT_SIZE="-0.146128035678238" METHOD="MH" MODIFIED="2010-09-07 12:09:43 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.4648187398462932" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="14" TOTAL_2="12" WEIGHT="0.0" Z="0.7309351999982757">
<NAME>Number of participants with severe dysfunction</NAME>
<GROUP_LABEL_1>Piroxicam</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7607858693862741" CI_START="0.2897593003801682" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.24570654427030766" LOG_CI_START="-0.5379626156267837" LOG_EFFECT_SIZE="-0.146128035678238" MODIFIED="2009-09-10 01:04:30 +0100" MODIFIED_BY="[Empty name]" ORDER="28" O_E="0.0" SE="0.46033114374845635" STUDY_ID="STD-Roldan-et-al-1990" TOTAL_1="14" TOTAL_2="12" VAR="0.21190476190476198" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" MODIFIED="2010-09-07 12:12:46 +0100" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Comparison of oral benzodiazepine (diazepam) versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6600512529016966" CI_START="0.26772935092671085" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-011.01" LOG_CI_END="0.22012149678027904" LOG_CI_START="-0.5723040148916416" LOG_EFFECT_SIZE="-0.17609125905568127" METHOD="MH" MODIFIED="2010-09-07 12:12:46 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.3837111463596513" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="15" TOTAL_2="12" WEIGHT="0.0" Z="0.8710787844607897">
<NAME>Number of participants with severe dysfunction</NAME>
<GROUP_LABEL_1>Diazepam</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.660051252901697" CI_START="0.26772935092671085" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.22012149678027912" LOG_CI_START="-0.5723040148916416" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2009-09-10 01:08:29 +0100" MODIFIED_BY="[Empty name]" ORDER="29" O_E="0.0" SE="0.46547466812563143" STUDY_ID="STD-Roldan-et-al-1990" TOTAL_1="15" TOTAL_2="12" VAR="0.21666666666666673" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" MODIFIED="2010-09-06 17:18:58 +0100" MODIFIED_BY="[Empty name]" NO="12">
<NAME>Comparison of oral benzodiazepine (prazepam) versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="35" EVENTS_2="39" I2="0.0" I2_Q="0.0" ID="CMP-012.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-09-06 17:18:50 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="63" TOTAL_2="58" WEIGHT="0.0" Z="0.0">
<NAME>Pain (5 milligrams prazepam)</NAME>
<GROUP_LABEL_1>Prazepam (5 mg)</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="12" I2="0.0" ID="CMP-012.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-12-23 17:50:20 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="19" WEIGHT="0.0" Z="0.0">
<NAME>No improvement in spontaneous TMJ pain</NAME>
<DICH_DATA CI_END="1.3815040265450342" CI_START="0.4536621675135456" EFFECT_SIZE="0.7916666666666666" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.14035215505328374" LOG_CI_START="-0.3432674365708379" LOG_EFFECT_SIZE="-0.10145764075877708" MODIFIED="2009-07-18 02:11:11 +0100" MODIFIED_BY="[Empty name]" ORDER="29" O_E="0.0" SE="0.28408054207559685" STUDY_ID="STD-Rossi-et-al-1983" TOTAL_1="20" TOTAL_2="19" VAR="0.08070175438596494" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="11" I2="0.0" ID="CMP-012.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-12-23 17:50:29 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>No improvement in TMJ pain during mastication</NAME>
<DICH_DATA CI_END="1.5431313341030672" CI_START="0.6093533273926" EFFECT_SIZE="0.9696969696969697" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.1884028899315695" LOG_CI_START="-0.21513081304753245" LOG_EFFECT_SIZE="-0.01336396155798149" MODIFIED="2009-07-18 02:11:30 +0100" MODIFIED_BY="[Empty name]" ORDER="30" O_E="0.0" SE="0.23703769465396995" STUDY_ID="STD-Rossi-et-al-1983" TOTAL_1="18" TOTAL_2="16" VAR="0.0561868686868687" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="16" I2="0.0" ID="CMP-012.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-12-23 17:50:37 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="0.0" Z="0.0">
<NAME>No improvement in TMJ pain on external palpation</NAME>
<DICH_DATA CI_END="1.1883461796396342" CI_START="0.4701965299113789" EFFECT_SIZE="0.7475" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" LOG_CI_END="0.07494297432077474" LOG_CI_START="-0.3277205803278401" LOG_EFFECT_SIZE="-0.12638880300353272" MODIFIED="2009-07-18 02:12:01 +0100" MODIFIED_BY="[Empty name]" ORDER="31" O_E="0.0" SE="0.23652656521733811" STUDY_ID="STD-Rossi-et-al-1983" TOTAL_1="25" TOTAL_2="23" VAR="0.0559448160535117" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="41" EVENTS_2="39" I2="0.0" I2_Q="0.0" ID="CMP-012.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-09-06 17:18:58 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="54" TOTAL_2="58" WEIGHT="0.0" Z="0.0">
<NAME>Pain (10 milligrams prazepam)</NAME>
<GROUP_LABEL_1>Prazepam (10 mg)</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="12" I2="0.0" ID="CMP-012.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-12-23 17:51:27 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="19" WEIGHT="0.0" Z="0.0">
<NAME>No improvement in spontaneous TMJ pain</NAME>
<DICH_DATA CI_END="1.8798677443900595" CI_START="0.8067304967370892" EFFECT_SIZE="1.2314814814814814" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" LOG_CI_END="0.27412729612430026" LOG_CI_START="-0.09327152516402816" LOG_EFFECT_SIZE="0.09042788548013607" MODIFIED="2009-07-18 02:13:29 +0100" MODIFIED_BY="[Empty name]" ORDER="26" O_E="0.0" SE="0.2158118862782604" STUDY_ID="STD-Rossi-et-al-1983" TOTAL_1="18" TOTAL_2="19" VAR="0.0465747702589808" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="11" I2="0.0" ID="CMP-012.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-12-23 17:51:34 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>No improvement in TMJ pain during mastication</NAME>
<DICH_DATA CI_END="1.7730246581403082" CI_START="0.7877466387528977" EFFECT_SIZE="1.1818181818181819" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" LOG_CI_END="0.24871477554440516" LOG_CI_START="-0.10361344124718162" LOG_EFFECT_SIZE="0.07255066714861175" MODIFIED="2009-07-18 02:14:04 +0100" MODIFIED_BY="[Empty name]" ORDER="27" O_E="0.0" SE="0.20695933859617893" STUDY_ID="STD-Rossi-et-al-1983" TOTAL_1="16" TOTAL_2="16" VAR="0.04283216783216784" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="16" I2="0.0" ID="CMP-012.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-12-23 17:51:41 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="23" WEIGHT="0.0" Z="0.0">
<NAME>No improvement in TMJ pain on external palpation</NAME>
<DICH_DATA CI_END="1.4924568468789574" CI_START="0.6784377482119053" EFFECT_SIZE="1.00625" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="16" LOG_CI_END="0.17390178272717857" LOG_CI_START="-0.16848999597532863" LOG_EFFECT_SIZE="0.002705893375924967" MODIFIED="2009-07-18 02:14:36 +0100" MODIFIED_BY="[Empty name]" ORDER="28" O_E="0.0" SE="0.20112262567649172" STUDY_ID="STD-Rossi-et-al-1983" TOTAL_1="20" TOTAL_2="23" VAR="0.040450310559006206" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-013" MODIFIED="2010-08-20 11:17:57 +0100" MODIFIED_BY="[Empty name]" NO="13">
<NAME>Comparison of oral propranolol versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-013.01" MODIFIED="2010-08-20 11:07:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="40" TOTAL_2="40" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Pain</NAME>
<GROUP_LABEL_1>Propranolol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-013.01.01" MODIFIED="2010-08-20 11:03:43 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>Reduction in pain intensity rating</NAME>
<CONT_DATA CI_END="0.08093865173820852" CI_START="-0.9809386517382086" EFFECT_SIZE="-0.45" ESTIMABLE="YES" MEAN_1="-0.46" MEAN_2="-0.01" MODIFIED="2010-08-20 11:03:43 +0100" MODIFIED_BY="[Empty name]" ORDER="66" SD_1="1.33" SD_2="1.08" SE="0.2708920449182663" STUDY_ID="STD-Tchivileva-et-al-2010" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="27" I2="0.0" I2_Q="0.0" ID="CMP-013.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-08-20 11:17:57 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>Pain</NAME>
<GROUP_LABEL_1>Propranolol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="27" I2="0.0" ID="CMP-013.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-08-20 11:17:57 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>Reduction in pain intensity (%)</NAME>
<DICH_DATA CI_END="0.5909234620431689" CI_START="0.09094673637770681" EFFECT_SIZE="0.23182441700960219" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="27" LOG_CI_END="-0.22846876643664943" LOG_CI_START="-1.0412128809719527" LOG_EFFECT_SIZE="-0.6348408237043011" MODIFIED="2010-08-20 11:17:57 +0100" MODIFIED_BY="[Empty name]" ORDER="63" O_E="0.0" SE="0.47740991602628857" STUDY_ID="STD-Tchivileva-et-al-2010" TOTAL_1="40" TOTAL_2="40" VAR="0.22792022792022792" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-013.03" MODIFIED="2010-08-20 11:05:09 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="40" TOTAL_2="40" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Pain</NAME>
<GROUP_LABEL_1>Propranolol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-013.03.01" MODIFIED="2010-08-20 11:05:09 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>Reduction in pain duration (% of day)</NAME>
<CONT_DATA CI_END="6.631914528398146" CI_START="-8.631914528398145" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="-4.5" MEAN_2="-3.5" MODIFIED="2010-08-20 11:05:09 +0100" MODIFIED_BY="[Empty name]" ORDER="67" SD_1="16.7" SD_2="18.1" SE="3.8939054944875076" STUDY_ID="STD-Tchivileva-et-al-2010" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-013.04" MODIFIED="2010-08-20 11:16:56 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="40" TOTAL_2="40" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Pain</NAME>
<GROUP_LABEL_1>Propranolol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-013.04.01" MODIFIED="2010-08-20 11:16:56 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>Change in pain index</NAME>
<CONT_DATA CI_END="-37.388683421442636" CI_START="-936.6113165785573" EFFECT_SIZE="-487.0" ESTIMABLE="YES" MEAN_1="-453.0" MEAN_2="34.0" MODIFIED="2010-08-20 11:16:56 +0100" MODIFIED_BY="[Empty name]" ORDER="69" SD_1="1167.0" SD_2="862.0" SE="229.3977441039907" STUDY_ID="STD-Tchivileva-et-al-2010" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2010-09-06 17:03:07 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Figure_14_review_August[1].PNG" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2010-09-06 16:58:18 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Results of the search.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlMAAANKCAIAAAAhjVxYAAB4o0lEQVR42u29vc4eOXa1rT4ENSZ1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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2010-09-06 17:00:42 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each entry in the risk of bias tool for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAT0AAAI0CAIAAADgHmmfAAAcMElEQVR42u3dsW7cxtrG8QXcuFCh
wlfga1BlCC4Md74nu1QRwCl9F4Yv4cBJyjiVKwM+lg4iFSkku8uJBR7qU76DPbskd8jlkPMufw+2
cDbyozF3/nxnhrPzrFZEFFEVEcURbolwS0S4JSLcEuGWiHBLRLglwi0R4ZaIcEuL6a+L77GuAkXq
rI1/xi1RDG7/23eXyTBuKSq36q3LQZH6q+uAWyLcEhFuiTY7q4MfcEtBe23jn3FLFADaxaKLW8It
bokmn+gaJxMRbokIt0TV/34ryDiZKEaXbfsDbolwi1si3OKWzG89B8ItEW6JCLdEbVNc42SiYNBu
/AG3RLjFLRFucUsLR3fJ0OKWCLdEhFuinVNc42SiYNAudoqL2yCfkM8It7gN10cr6Ti4xW1Ebqtl
J9A1XofKcyAqn1si3MarLUS4peC91rlwugKFmztYl8JtmArjsRBucRuspxJucYvbAxl9mN8Sbgm3
lGdya36rS+CWcItbIqMP3FJlJYZwewAjQx+ZLoFb3AYeIRsnE27jXRDPb8n81l0Mt0S4xS2R0Qdu
w9QWKzGEWyLckhndTMNjz4Fwq6dGvZGZ31KYeutqLPz64JZwi1uaasDsangOhNsYFUZYAeE2KrfQ
Jdzi1qwBt5QfXdDmmDXEugXglow+4j0Qxm2knkoTcFtFyCvFLW7NGuJdYdzG+ZA8v81/kXFLRLgl
ItwGHSqb7k48HynzauM2Rn9q+wNlutSFX23c4vYQCuPo0K6/g1vC7chXY8RLgVvKW2HcxTLdxRqv
M26JjD5wS4tH1/fmKcw4eazNfT79Ca4zbpdeXjJ5xuoA+c6Xss+RInFbRfgGTJX/VFrcUjBuF341
cEsT1ZmxbF3e3NcZt0TNgC30CugKRuBRxopOpcVtvAozVk+NmzyU75wa42QqvadGqa5TXg31lvTU
iS7IBN8rwC0Vx601noizBtyG7Fj5Koz7o3Ey6amRqiJuCbcTNXuZow/cBq4zmZzD3WtGjwgyv6WM
FWaxa0hm6bgN3FMX+8FZAMft0rl1MnPEOwJuA/enEXPo7Oio7LugcD0Vt7gl3OIWt2RG52rglg6G
rsr3b4mM7XFLMSqM780bJ1Ownup7891Xw7oU4TbXGGH064xbwm3IS12FOALeB7bMClM576LzUhR7
TXCrvBwCYAu9xejBuNVm3FKYeVe4Tz9rg3M8b8s4uwFGrJ66wBMeJuA234nqo7cct4vmNvYoMdu5
cJm4rcbLK8VtyJ7qLhax3honU5YR8sLHyZnujzmuKm5JyQ1729UVljmjO5iRwtJuB7hdenlxR5js
Oo84bMbtovuTDOiJK/lYK164xe2Y/WkWwAJ9grhVBxbKbcSn2biloudduO0mbawG45bCzxp8H4hK
HypXnl7aPYbbcEPZ0SuMO8I0V2PcFQrcLppbZ5rOcp3Nb/WnJXKbO2++/OuM20XP6DwHwi25I8Tm
tsp8/t76rzBOJveapV4BXSFQN/WRZb3OuKWJBopjuRknV2Mf4/bfBWTPgWiJiTjV5Gd0lIwGbnEb
httpWhhiJoLbkPPbfOau8zQfIm5p6XexBT5zxi2ZMuRaPcKtCpNrPeYAnjAtcG8mbuN1zaxJzYst
uVWeVbpM91zchuyXS86tnmbQUfjoA7e4pXhXA7chi0zWmbOrjVuiMHexKs6uT9ySWUO8+Qhug1WY
KvO5R7jFLY3cU/OdwxBicDhBm6OsI+AWt8G4reypxi1uI3JLuA02v/V9oOjrCJV9jkSxxjXOcyTC
LcXpUgs/Xwq3uNWfYq8nV3GeZjvvAree32a5GrG6BG6rJffUuPulcIvbGJ+TWWgmbif4/q39UuQu
Fn5PtXpLhFuiaAzkGM1WOfNccEvLHR7nOy21/JkzbsEQ/gzx0Z3LXwLEbTC6qgjnsAb9lkKg5+S4
1Z8y1sMJ7guF75cyTsZtPG6rtSfPJc9Cw43tcbt0bkef306QcxmOW/Pbpc9voywdBV09yvq9K98r
IHexLFsRJ5uPmN8uaJycYyzqnBrcUt7CUn4u686W4xa3y623USp5BxIF3sWqnN+7Mr+lANy2Oets
Y94FXIhwA+bC57e4xa0PaRWx6zfeEXJsQsItBeB24VUrx9h+yhUE3OJ2X8+IudX5uM2369M+R+iu
go6Tc69Uj97a3F8twC0VVLsmGHlmYizQaBm3yyV24h0dhFuMBaiKB3Cpi3XG7SEMbhd1r8k3c55+
FwpuoVsWAxFvW7ilGH034o4O3OI26vx29J4a6Mlw1u5qfkuR6nasnVjhxva5roAeDN3FZu3gliYq
LyXXGU+GcUsNnTXQPsdMbdZjcRsMgNE7bia6Jj4BB7e0IG4jOk8zyK+ynVNTjRgXho1YU9wolTxo
unS+c+HGcsatO0K8AWfc85NxS2YNVeF04VZnzTXvmqwqhpg52y9FAeZdU86cQ8zJg93HsbHw9ZJ8
Y05zctziFrdR5yOeAy16fhvlOVDokyKtS9FC7wjTAFZlC7/FLVEuaAunC7eKYZgx5/Tfm/cciJYy
Mox4Rwg9ts9yBYCxzJEhTXNVnXuuP5XObdxKjlsqfWR4SOPk8p9dyQcitzDdFbdhP7OSnTf2BkXZ
+Yxbyjg4LNy5bem75B2UcqspI1Ql75idktusCZr5jrAb/zkzPELM5fKNNgNxm/s645bUW9ziFsBB
5rf58uA54zY2wLGcKcut1oUgwi0R4ZaIcEuEWyLC7QI/AKI+z4pwOz+3nDn3dcYtbjnjlvRUzrjF
LWfOuMUtZ9yS/sQZt7jd1u3t9c3N2dXV6cXF8Zcvq/Pzo8vLk+vrV7e3fxTrfP3X9dn52elvp8c/
H6/+sTr66ejk15NX/3z1x785j+OM26K5/fbtzcXFoxqq7VcN29evPxbo/Ob3N49+eVR30O1X3XF/
/BfnEZxxWy63delr5Gr9Vf9MUc51GWnso+uv+mc47+mM20K5revhTrTuX221cXrnurbs7Kb3r7Y6
w3lObtu2a8147n7iL2r7scaWb1+69De7f2M981wfxL5/v3r6dPXw4d3rxYvVhw+bw9rv369md65n
cW0DwsYh4tWfnIc45+U2vfeXz20jitt/Tn9z52+8uTlb5+fx47sGvHu3evv27g9PniSNaSd2Pjs/
S+ymHeNDzqVzu34cWUqN2ji+rPtAs+063/jPbPst220ehdv0a3V1ddo4cP306a61dW3ceP/y8mR2
59PfTht65L2aeurJr5yHOM/J7TZ+KQB0//V0qAZgtie3fcfJ9w9mNl4fP66ePVs9eLB6/Xrzf52f
H83ufP+QI72nHv3EeYjzbPPbned09hpw7gnkntzuvJt0T+/b3mwsic+f31m9fNm8hjS7c3MfXddW
Z+U8wHmeetsxLt0e1rZ1+p3cpiyJbfzksHWp7cZsj+cHzG8bq2JdD2t9/tyA1p71dhRnVfEQ6m36
ODmx6A2rt2OV5e4rmFjA07ltm4W2vfaf3+7vbBZqfttj8Lz//HZAvZ14Pfn+da/0PRITO1v1PYT1
5MSxbt/15O5havdfTxnrlvn8tpuufZ7fjujsKWv457dTKvpmL/ulOJeyX2qCvp4vLKec+479yZwP
tt4eMLfV39/aOW7/1s4PBTrXdaZ5NfX/BoQ/XHAewRm3pY/z274l2zjzLMS57RunjbM4zrg1P+e8
CGfc4pYzbklP5Yxb3HLmjFvccsYt6U+ccbtMbonk8am3nNVbwi1n3JKeyhm3uOWMW8ItZ9ySnsoZ
t0vkVh5fdOe/rq/Pz85+Oz39+fj4H6vVT0dHv56c/PPVq3//IY/vQLmVxxfd+fc3b3559KjxO/M1
xv/6UR7fwXHrvIvoznVR3XlMTf0zuD0cbp0vFd25rrSJxzm2Vd0puN0ns2uCvK8Z8/iq/scvy+OL
7lzPaduGx40D5j+vrg6B27kW/UbP46s6w4EqeXwH6nx+dtbHuHm0PD+33fl63bl7VdoByx3/d/Y8
vr7cyuOL7vzb6Wkvbn89OSmO2175er1+rNojQGSaPL5h42R5fNGd7x/5pL9+OjqajduUbyHtzC5I
L2IpJMyexzeMW3l80Z3b7gbtxqvi6m21K/muY7zaPWncmbI3ex7fiPVWHp96W8Q4uePNfXKxisrj
G/bX5fGZ3xbE7c48232y+QbPb7Pm8Q3jVh6f9eSCxslVcn78PuPkqrA8vv2f38rj8/w2F7c07oNl
+6WiO8fYL0XjclvZnxzf2f7kJXJbyeOL71xX3ba15fr9ix/k8R0it5U8vvjObd+/bZzT4vZAuOXM
Gbe45Yxb0p844xa3nDnjFreccUv6E2fcUiWPj+Txqbec1VvCLWfckp7KGbe45Yxbwi1n3JKeyhm3
i+U2X06cPL641xm3RXObLydOHl/o64zbcrnNdw6D8y6iX2fcFsptvnOPnC8V/TqPw+0EaXqTLR50
H48+4pvdvzHfOYPy+KJfZ9z2/rfsc5J7lXwge5XzXF95fNGv80TcpiTxbWfnddertpC+tr+yTx5f
479rREQnPkdfHl/06zwFtylJfAOi97oTBnLk8U3Mbb7cGnl80a/zmNy2ff+ob1RXYhcfJWdkp3OK
7bBW7YY5W06cPL7o13miepsIc5UQKZJOyOh5fBNzO3EdkMcX6DpPPU7uy+q4hMTKrZ5+3iWPL8p1
nnN+O4DbXvW21/w2pSwPXmSu+qRsT7/OKY8v3HWeeT257zi57wrQWHl8beeGJD6q3XnsyLzPFeXx
hbvOo3FLOR4s2y8V3bn0/VKUg9vK/uT4zvYnL5HbKmdOnDy+0NcZt0VzW+XMiZPHF/c647Z0bjlz
xi1uOeOW9CfOuMUtZ864xS1n3JL+xBm3VMnjI3l86i1n9ZZwyxm3pKdyxi1uOeOWcMsZt6Sncsbt
YrmVbRfd+a/r6/Ozs99OT38+Pv7HavXT0dGvJyf/fPXq33/I4ztQbmXbRXf+/c2bXx49avw2fo3x
v36Ux3dw3Do7IrpzXVR3HoBT/wxuD4dbZzVFd64rbeJBkW1VdzZu2456nP5OMVceX2nnOXKexrme
07YNjxsHzH9eXZXL7YyFfa48vpSbwvabziKO7nx+dtbHuHm0XAS3HX29bx5flRAqW1oeX6+cEWf/
R3f+7fS0F7e/npyUyG1b4R2cx7dPhez1Y6Nw2zdnRNZOdOf7Rz7pr5+Ojorjtm8QSS9CEov8vHl8
fbmVbRfdue1u0G68KovbRnT35LZ7nFxgHp96q97Gq7fDsBy82FNaHt+AXC9zRfPbEteTRxwny+Oz
6ms9eernt71yqwevJ1fz5fEN49azUM9vK/ulSpa9R4fqHHi/FA3mtrLXN76z/clL5LaSbRffua66
bWvL9fsXP8jjO0RuK9l28Z3bvn/bOKfF7YFwy5kzbnHLGbekP3HGLW45c8YtbjnjlvQnzrilSh4f
yeNTbzmrt4RbzrglPZUzbnHLGbeEW864JT2VM24Xy61su3Xd3l7f3JxdXZ1eXBx/+bI6Pz+6vDy5
vn51e7usNuO2aG5l263r27c3FxeP6q6//aqR+Pp1QW3GbbncOjvif+rh9avG3r/+qn9mIW3GbaHc
Oqtpo2rtBOD+1VbBDqnNs3Gb/hvHattceXw7G+BsxJ3O9fxwfaj5/v3q6dPVw4d3rxcvVh8+bA4+
v38/5DbjNunHRjnVufvI2O03nUW8rpubs/Ve/vjx3cV892719u3dH548SRp5HkybS+S2LSAveh5f
X26d/b+uq6vTxuHlp0933nUF23j/8vKQ21wct20wpKccJELV68f257Y7qlvWzk7n+8cnG6+PH1fP
nq0ePFi9fr35v87PD7nNYbjtVdmq8vL4BnAr225djYXr+fM7y5cvm1d6DrjNh8xtOXl8fRPD1NvE
2lVXrVqfPzcAUGy9HaXNi6i3Y5XlwXl8O78GbX47eK7Y9ip5frt/m81vJ8rjG1BvrSd3rM3ev+6V
vpPhYNo8M7dto9kc68nVrHl8nt+O+yy0m4Eyn9+O2OY5uaWdn439UuuyXwq3Mbit7E/eqI32J+M2
BLeVbLutCta4Tvv/361ZUJtxWzS3lWy7rXlj43dZG+eHB9xm3JbOLWfOuMUtZ9yS/sQZt7jlzBm3
uOWMW9KfOOOWKnl8JI9PveWs3hJuOeOW9FTOuMUtZ9wSbjnjlvRUzrhdLLfy+DjjNhi38vg44zYY
t8674IzbYNw6X4rzRNymHz5a7PJPpjy+xOPU12dEznPkPB23HeeDB+V2/9PYd2403X7T+cmcp663
O7tvR0fvPvJ/+4fLz+PrDgeq5BVw7uk8Kbc7wwHa/m56iEF6hez1Y3tyO2ycLB+I8wzz28RkkJQC
dQB5fAO4lcfHeZ51qcH4bf/F7tS8wvP41FvOYertuNymI5T4VwaU5cF5fMO4NaPjPNtzoLYove43
96xsVZF5fNaTOZe+ntzRvxuXmrpXoXeu+iY+cZ03j8/zW87lPr8d61HqovZv2SHEeeb9Ut29c+dR
VwuEtrIjl7P9yQfGbSWPjzNuI3JbyePjjNuI3HLmjFvccsYt6U+ccYtbzpxxi1vOuCX9iTNuqZLH
R/L41FvO6i3hljNuSU/ljFvccsYt4ZYzbklP5YzbxXJ7e3t9c3N2dXV6cXH85cvq/Pzo8vLk+vrV
7e0fxTrny7bTZtwG4PbbtzcXF4/qD3v7VXeCr19/LNA5X7adNuM2ALf1Lbnx815/1T9TlHO+Ex60
GbcBuK3v0zs/8vtX2z17eud8Jyppc3Zu0/dqdTRu9FvJPnl8Vec5j8Pe7P6N9YxofXD1/v3q6dPV
w4d3rxcvVh8+bA63vn+/mt053wmG2jwRt72YKZ/b7pzBfSJR2t68uTlb/1wfP75rwLt3q7dv7/7w
5EnSWGti53wnBmvz/NzuPAy57YzlufL4GgP1cnN7dXXaOKD69OmutfU9e+P9y8uT2Z3zndCvzTNz
uzOqb7u+FZLHNzG39w8MNl4fP66ePVs9eLB6/Xrzf52fH83unC8RR5tnnt8mcruzi0+fx9fGbXqW
Si9uG2/Vz5/f2b582by2MbtzvgQ6bZ663vYqU92D53nz+FIySqq0bO7Bd+v6Pl3r8+eGj3zPejuK
88S1a7FtnmicvGe93TPXa6yy3DvANs/8tu21//x2f+fp54rLbHO53O45+Bw9j2/6+e3GauT9617p
z+4ndp5sbXbhbQ62ntwXhrHy+Ep4ftv9qe/z/HZE58mehS68zbm4pVEeLNsvpc24jcdtZX+yNuM2
IrfV398mOW7/NskPBTrny7bTZtzG4LZq//Zm44yoEOd82XbajNsY3HLmjFvccsYt6U+ccYtbzpxx
i1vOuCX9iTNuqZLHR/L41FvO6i3hljNuSU/ljFvccsYt4ZYzbklP5YzbxXIrj0+bcRuMW3l82ozb
YNw670KbcRuMW+dLafP83PYN6Rt9VUAeX25neXzTtHlqbidbhRudW3l8Kc7y+KZpc0Hc7lO7Us5P
njGPL+WmsP2mPD5tLp3bPWtX4Xl8w7iVx6fNpc9v0/nJEfyzJ7eNqQgdwQiJ/yh5fNpcXL1NDxAa
Nk6eK48vd72Vx6fNM4+Td9bb9O5eTh7fBPNbeXzaXDS3U85v5fHJ45PHV+J6ciWPL7+zPL5p2jwp
t9T3wbL9UtqM23jcVvYnazNuI3JbyePTZtxG5LaSx6fNuI3ILWfOuMUtZ9yS/sQZt7jlzBm3uOWM
W9KfOOOWKnl8JI9PveWs3hJuOeOW9FTOuMUtZ9wSbjnjlvRUzrhdLLf5cuIiOkfM48vhjNuiuc2X
ExfROWIeXyZn3JbLbb5zGCI6RzzvIp8zbgvlNt+5RxGdI54vlc85idte269G78Qdv3ey280oRzf2
Os8x3zmDEZ0j5vHlc+5db0uI7Zt+aDDKUcl9z2HNd65vROeIeXz5nEfgdufJwI1nHbeVqSotfKCN
k5Tf1d2AnddhMm7znaMf0TliHl8+5325TYmf3O7Z2728LSMrndtevyvxr4/IbdstqeM35sutiegc
MY8vn/OY4+Qc3X1/bkdpwM77VA5u8+XERXSOmMeXz3nMcfKAtLuiuE38xuM+k171dlF5fOXW22Hj
5MLr7T7/9mE3BfPbwfPbkvP4Asxvu+el6fU2ZX6bY0g8IDJvlBuQ9eRh68kh8vgCrCdXnaF4iTPA
jvXklOe3A2LsU3LiOxrg+e1cz29D5PEV9PyWpnlkfS/7pdZlvxRuY3Bb2Z+8UcHsT8ZtCG6rnDlx
EZ0j5vFlcsZt0dxWOXPiIjpHzOPL4Yzb0rnlzBm3uOWMW9KfOOMWt5w54xa3nHFL+hNn3FIlj4/k
8am3nNVbwi1n3JKeyhm3uOWMW8ItZ9ySnsoZt4vlVh4fZ9wG41YeH2fcBuPWeReccRuMW+dLcR6B
2/RNWMNOM8x979gnk6HX0Y0DUpQaZ0TOc+Q8Zr1ND78qZFFuT24HnOe686/vbJjzkzln57ZXEF7b
Ox1HE3fnAHSPDnbWxo5TlxNHBxtvjsKtvALOebntlXmXwm0v2odVyF4/ls7tzv9M51Y+EOeJuE3k
YSeu6aUsN5Aptpm4lcfHOR63bUF+jWPpxGiSAYmBM3KrwnAOXG8TJ8PDFrR7leV0Gs1vOUed3/Za
gO37k1WfCL+U+W1KWU6svWNxawWV8zzryYO57Xhe2vhLE5+4doyod+Kdnsfn+S3nQp/f0jQPlu0Q
4ozbeNxWduRyxm1Ebit5fJxxG5HbSh4fZ9xG5JYzZ9ziljNuSX/ijFvccuaMW9xyxi3pT5xxS5U8
PpLHp95yVm8Jt5xxS3oqZ9ziljNuCbeccUt6KmfcLpbb29vrm5uzq6vTi4vjL19W5+dHl5cn19ev
bm//KNY5X7ZdxDbL41sct9++vbm4eFR30O1X3XG/fv2xQOd82XYR2yyPb3Hc1mWksY+uv+qfKco5
3wkPEdvsvIvFcVvXlp3d9P7VVmemd853olLENhd9vlTKKaQl3BemyePrldzX8RvrWdz6gPD9+9XT
p6uHD+9eL16sPnzYHCJ+/341u3O+Ewwjtrn08xz7hveE4zb9WNleB9B2v3lzc7beFx8/vvuM3r1b
vX1794cnT5LGhxM75zsxOGKbizs/OZ3bjrCC9DKVws/OI4unzOMbhdurq9PGQeCnT3etrevMxvuX
lyezO+c7oT9im4vLK9jZm3dm//Tq7ilpmn0rZK8fm4Xb+4ccG6+PH1fPnq0ePFi9fr35v87Pj2Z3
zpeIE7HNxeUDtbkPy8jMgdlceXwjcttYXp4/v/ukXr5sXo+Z3TlfAl3ENheXxxeC21ny+HLX27q2
1Pr8uaGb7llvR3GeuN4W3mb1dq96u8+CU+Ky+ZTz27bX/vPb/Z2nn9+W3OYA89usy7CJk+R95rdj
5fHlW0++f90rfb/BxM6TrSeHaHPp68n79+zE9eQqLT6vY6F4gjy+TM9vu3vqPs9vR3Se7PltiDbL
4ztw2S91qG2Wx7dEbiv7k+O32f7kJXJb/f0NmOP2b8D8UKBzvmy7iG2Wx7dEbqv2b5w2zuIKcc6X
bRexzfL4lsgtZ864xS1n3JL+xBm3uOXMGbe45Yxb0p8445YqeXwkj49oWbd7F4IIt0SEWyLCLRFu
iQi3RIRbosPklohi6T8NoTwn/Zqd5AAAAABJRU5ErkJggg==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2010-09-06 17:01:13 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each entry in the risk of bias tool presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAfMAAADnCAMAAAA94U9AAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2010-09-06 17:09:39 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2010-09-06 17:04:05 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-09-06 17:04:00 +0100" MODIFIED_BY="[Empty name]">Cochrane Oral Health Group's Trials Register search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-09-06 17:04:05 +0100" MODIFIED_BY="[Empty name]">
<P>((craniomandibular or cranio-mandibular or "cranio mandibular" or "temporo mandibular" or temporo-mandibular or temporomandibular or "orofacial pain" or "myofasc* pain" or "facial pain" or "facial arthromyalgia" or "myofasc* syndrom*") AND (analgesic* or anti-inflammat* or antiinflammat* or "anti inflammat*" or steroid* or "anti depress*" or antidepress* or anti-depress* or anticonvulsant* or anti-convulsant* or "anti convulsant*" or capsaicin or acetaminophen* or paracetamol* or ibuprofen* or codeine* or morphine* or tramadol* or amantadine* or amitriptyline* or carbachol* or carbamazepine* or cimetidine* or "dimethyl sulfoxide" or interleukin-2 or quinine* or tetrahydrocannabinol* or buprenorphine* or enkaphalin* or fentanyl* or heroin or meperidine or anaesthetic* or anasthetic* or baclofen* or diazepam* or sertraline* or bupropion* or citalopram* or fluoxetine* or fluvoxamine* or mianserin* or paroxetine* or sulpiride* or trytophan* or anitriptyline* or clomipramine* or desipramine* or imipramine*))</P>
<P>((craniomandibular or cranio-mandibular or "cranio mandibular" or "temporo mandibular" or temporo-mandibular or temporomandibular or "orofacial pain" or "myofasc* pain" or "facial pain" or "facial arthromyalgia" or "myofasc* syndrom*") AND (acetazolamide* or carbamazepine* or diazepam* or "magnesium sulphate*" or melatonin* or phenobarbital* or phenytoin* or propofol* or thiopental* or valproic* or valproate* or vigabatrin* or aspirin* or curcumin* or dapsone* or diclofenac* or indomethacin* or ketoprofen* or mesalamine* or naproxen* or piroxicam* or salicylate* or sulfasalazine* or painkiller* or pain-killer* or analgaes* or analges* or NSAID* or SSRI* or "selective serotonin*" or rofecoxib* or celecoxib* or meloxicam or muscle-relax* or doxepin* or topical or amitriptyline* or gabapentin* or meprobramate* or clonazepam* or lorazepam* or dothepin* or paroxetine* or pharm*))</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2010-09-06 17:06:20 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2009-11-15 01:03:47 +0000" MODIFIED_BY="[Empty name]">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-09-06 17:06:20 +0100" MODIFIED_BY="[Empty name]">
<P>#1        MeSH descriptor Craniomandibular Disorders explode all trees</P>
<P>#2        MeSH descriptor Myofascial Pain Syndromes explode all trees</P>
<P>#3        ((masticat* in All Text or myofasc* in All Text or orofacial* in All Text) and (pain* in All Text or dysfunction* in All Text or syndrom* in All Text))</P>
<P>#4        (temporomandibular* in All Text or temporo-mandibular* in All Text or craniomandibular* in All Text or cranio-mandibular* in All Text)</P>
<P>#5        (("facial pain" in All Text near/3 psychogenic* in All Text) or ("facial pain" in All Text near/3 atypical in All Text) or ("facial pain" in All Text near/3 chronic in All Text))</P>
<P>#6        (tmd* in Title, Abstract or Keywords or cmd* in Title, Abstract or Keywords or tmd* in Title, Abstract or Keywords)</P>
<P>#7        "facial arthromyalgia*" in All Text</P>
<P>#8        (mpds in All Text and not (myeloprolif* in All Text or myelo-prolif* in All Text))</P>
<P>#9        (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8)</P>
<P>#10      MeSH descriptor Analgesics explode all trees</P>
<P>#11      MeSH descriptor Anti-Inflammatory Agents, Non-Steroidal explode all trees</P>
<P>#12      MeSH descriptor Steroids explode all trees</P>
<P>#13      MeSH descriptor central nervous system depressants explode all trees</P>
<P>#14      MeSH descriptor Muscle Relaxants, Central explode all trees</P>
<P>#15      MeSH descriptor antidepressive agents explode all trees</P>
<P>#16      MeSH descriptor anticonvulsants explode all trees</P>
<P>#17      MeSH descriptor Capsaicin this term only</P>
<P>#18      (acetaminophen* in All Text or paracetamol* in All Text or ibuprofen* in All Text or codeine* in All Text or morphine* in All Text or tramadol* in All Text or amantadine* in All Text or amitriptyline* in All Text or</P>
<P>carbachol* in All Text or carbamazepine* in All Text or cimetidine* in All Text or "dimethyl sulfoxide*" in All Text or interleukin-2 in All Text or quinine* in All Text or tetrahydrocannabinol* in All Text or buprenorphine* in All Text or enkaphalin* in All Text or fentanyl* in All Text or heroin in All Text or meperidine in All Text)</P>
<P>#19      steriod* in All Text</P>
<P>#20      (anaesthetic* in All Text or anasthetic* in All Text or baclofen* in All Text or diazepam* in All Text)</P>
<P>#21      (sertraline* in All Text or bupropion* in All Text or citalopram* in All Text or fluoxetine* in All Text or fluvoxamine* in All Text or mianserin* in All Text or paroxetine* in All Text or sulpiride* in All Text or trytophan* in</P>
<P>All Text or anitriptyline* in All Text or clomipramine* in All Text or desipramine* in All Text or imipramine* in All Text)</P>
<P>#22      (acetazolamide* in All Text or carbamazepine* in All Text or diazepam* in All Text or "magnesium sulphate*" in All Text or melatonin* in All Text or phenobarbital* in All Text or phenytoin* in All Text or propofol* in All Text or thiopental* in All Text or valproic* in All Text or valproate* in All Text or vigabatrin* in All Text)</P>
<P>#23      (aspirin* in All Text or curcumin* in All Text or dapsone* in All Text or diclofenac* in All Text or indomethacin* in All Text or ketoprofen* in All Text or mesalamine* in All Text or naproxen* in All Text or piroxicam* in All Text or salicylate* in All Text or sulfasalazine* in All Text)</P>
<P>#24      (painkiller* in All Text or pain-killer* in All Text or analgaes* in All Text or analges* in All Text or NSAID* in All Text or SSRI* in All Text or "selective serotonin*" in All Text or rofecoxib* in All Text or celecoxib* in All Text or meloxicam in All Text or muscle-relax* in All Text or doxepin* in All Text or topical in All Text or amitriptyline* in All Text or antidepress* in All Text or anti-depress* in All Text or gabapentin* in All Text or meprobramate* in All Text or clonazepam* in All Text or lorazepam* in All Text or dothepin* in All Text or paroxetine* in All Text or pharm* in All Text)</P>
<P>#25      (#10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24)</P>
<P> #26      (#9 and #25)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2010-09-06 17:07:52 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2010-09-06 17:07:05 +0100" MODIFIED_BY="[Empty name]">MEDLINE via OVID search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-09-06 17:07:52 +0100" MODIFIED_BY="[Empty name]">
<P>1.      exp Craniomandibular Disorders/</P>
<P>2.      exp Myofascial Pain Syndromes/</P>
<P>3.      ((masticat$ or myofasc$ or orofacial$) and (pain$ or dysfunction$ or syndrom$)).mp.</P>
<P>4.      (temporomandibular$ or temporo-mandibular$ or craniomandibular$ or cranio-mandibular$).mp.</P>
<P>5.      (facial pain adj3 (psychogenic$ or atypical or chronic)).mp.</P>
<P>6.      (tmj$ or cmd$ or tmd$ or 'facial arthromyalgia$').mp.</P>
<P>7.      (mpds not (myeloprolif$ or myelo-prolif$)).mp.</P>
<P>8.      or/1-7</P>
<P>9.      exp ANALGESICS/</P>
<P>10.  exp Anti-inflammatory agents, Non-Steroidal/</P>
<P>11.  exp Steroids/</P>
<P>12.  exp central nervous system depressants/ or exp muscle relaxants, central/</P>
<P>13.  exp Antidepressive Agents/</P>
<P>14.  exp Anticonvulsants/</P>
<P>15.  exp Capsaicin/</P>
<P>16.  (acetaminophen$ or paracetamol$ or ibuprofen$ or codeine$ or morphine$ or tramadol$ or amantadine$ or amitriptyline$ or carbachol$ or carbamazepine$ or cimetidine$ or 'dimethyl sulfoxide$' or interleukin-2 or quinine$ or tetrahydrocannabinol$ or buprenorphine$ or enkaphalin$ or fentanyl$ or heroin or meperidine).mp.</P>
<P>17.  steroid$.mp.</P>
<P>18.  (anaesthetic$ or anesthetic$ or baclofen$ or diazepam$).mp.</P>
<P>19.  (sertraline$ or bupropion$ or citalopram$ or fluoxetine$ or fluvoxamine$ or mianserin$ or paroxetine$ or sulpiride$ or tryptophan$ or amitriptyline$ or clomipramine$ or desipramine$ or imipramine$).mp.</P>
<P>20.  (acetazolamide$ or carbamazepine$ or diazepam$ or 'magnesium sulphate$' or melatonin$ or phenobarbital$ or phenytoin$ or propofol$ or thiopental$ or valproic$ or valproate$ or vigabatrin$).mp.</P>
<P>21.  (aspirin$ or curcumin$ or dapsone$ or diclofenac$ or ibuprofen$ or indomethacin$ or ketoprofen$ or mesalamine$ or naproxen$ or piroxicam$ or salicylate$ or sulfasalazine$).mp.</P>
<P>22.  (painkillers$ or pain-killer$ or analgaes$ or analges$ or NSAID$ or SSRI$ or 'selective serotonin$' or rofecoxib$ or celecoxib or meloxicam or muscle-relax$ or doxepin or topical or amitriptyline$ or antidepress$ or anti-depress$ or gabapentin$ or meprobamate$ or clonazepam$ or lorazepam$ or diazepam$ or dothiepin$ or paroxetine$ or fluoxetine$ or pharm$).mp.</P>
<P>23.  or/9-22</P>
<P>24.  8 and 23</P>
<SUBSECTION>
<HEADING LEVEL="3">Cochrane search filter for MEDLINE via OVID</HEADING>
<P>Cochrane Highly Sensitive Search Strategy (CHSSS) for identifying randomised trials in MEDLINE: sensitivity maximising version (2009 revision) as referenced in Chapter 6.4.11.1 and detailed in box 6.4.c of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> version 5.0.2 (updated September 2009).</P>
<P>1. randomized controlled trial.pt.<BR/>2. controlled clinical trial.pt.<BR/>3. randomized.ab.<BR/>4. placebo.ab.<BR/>5. drug therapy.fs.<BR/>6. randomly.ab.<BR/>7. trial.ab.<BR/>8. groups.ab.<BR/>9. or/1-8<BR/>10. exp animals/ not humans.sh.<BR/>11. 9 not 10</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2010-09-06 17:08:30 +0100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2010-09-06 17:08:18 +0100" MODIFIED_BY="[Empty name]">EMBASE via OVID search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-09-06 17:08:30 +0100" MODIFIED_BY="[Empty name]">
<P>1.      exp Craniomandibular Disorders/</P>
<P>2.      exp Myofascial Pain Syndromes/</P>
<P>3.      ((masticat$ or myofasc$ or orofacial$) and (pain$ or dysfunction$ or syndrom$)).mp.</P>
<P>4.      (temporomandibular$ or temporo-mandibular$ or craniomandibular$ or cranio-mandibular$).mp.</P>
<P>5.      (facial pain adj3 (psychogenic$ or atypical or chronic)).mp.</P>
<P>6.      (tmj$ or cmd$ or tmd$ or 'facial arthromyalgia$').mp.</P>
<P>7.      (mpds not (myeloprolif$ or myelo-prolif$)).mp.</P>
<P>8.      or/1-7</P>
<P>9.      exp ANALGESICS/</P>
<P>10.  exp Anti-inflammatory agents, Non-Steroidal/</P>
<P>11.  exp Steroids/</P>
<P>12.  exp central nervous system depressants/ or exp muscle relaxants, central/</P>
<P>13.  exp Antidepressive Agents/</P>
<P>14.  exp Anticonvulsants/</P>
<P>15.  exp Capsaicin/</P>
<P>16.  (acetaminophen$ or paracetamol$ or ibuprofen$ or codeine$ or morphine$ or tramadol$ or amantadine$ or amitriptyline$ or carbachol$ or carbamazepine$ or cimetidine$ or 'dimethyl sulfoxide$' or interleukin-2 or quinine$ or tetrahydrocannabinol$ or buprenorphine$ or enkaphalin$ or fentanyl$ or heroin or meperidine).mp.</P>
<P>17.  steroid$.mp.</P>
<P>18.  (anaesthetic$ or anesthetic$ or baclofen$ or diazepam$).mp.</P>
<P>19.  (sertraline$ or bupropion$ or citalopram$ or fluoxetine$ or fluvoxamine$ or mianserin$ or paroxetine$ or sulpiride$ or tryptophan$ or amitriptyline$ or clomipramine$ or desipramine$ or imipramine$).mp.</P>
<P>20.  (acetazolamide$ or carbamazepine$ or diazepam$ or 'magnesium sulphate$' or melatonin$ or phenobarbital$ or phenytoin$ or propofol$ or thiopental$ or valproic$ or valproate$ or vigabatrin$).mp.</P>
<P>21.  (aspirin$ or curcumin$ or dapsone$ or diclofenac$ or ibuprofen$ or indomethacin$ or ketoprofen$ or mesalamine$ or naproxen$ or piroxicam$ or salicylate$ or sulfasalazine$).mp.</P>
<P>22.  (painkillers$ or pain-killer$ or analgaes$ or analges$ or NSAID$ or SSRI$ or 'selective serotonin$' or rofecoxib$ or celecoxib or meloxicam or muscle-relax$ or doxepin or topical or amitriptyline$ or antidepress$ or anti-depress$ or gabapentin$ or meprobamate$ or clonazepam$ or lorazepam$ or diazepam$ or dothiepin$ or paroxetine$ or fluoxetine$ or pharm$).mp.</P>
<P>23.  or/9-22</P>
<P>24.  8 and 23</P>
<SUBSECTION>
<HEADING LEVEL="3">Filter for EMBASE via OVID</HEADING>
<P>1. random$.ti,ab.<BR/>2. factorial$.ti,ab.<BR/>3. (crossover$ or cross over$ or cross-over$).ti,ab.<BR/>4. placebo$.ti,ab.<BR/>5. (doubl$ adj blind$).ti,ab.<BR/>6. (singl$ adj blind$).ti,ab.<BR/>7. assign$.ti,ab.<BR/>8. allocat$.ti,ab.<BR/>9. volunteer$.ti,ab.<BR/>10. CROSSOVER PROCEDURE.sh.<BR/>11. DOUBLE-BLIND PROCEDURE.sh.<BR/>12. RANDOMIZED CONTROLLED TRIAL.sh.<BR/>13. SINGLE BLIND PROCEDURE.sh.<BR/>14. or/1-13<BR/>15. ANIMAL/ or NONHUMAN/ or ANIMAL EXPERIMENT/<BR/>16. HUMAN/<BR/>17. 16 and 15<BR/>18. 15 not 17<BR/>19. 14 not 18</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2010-09-06 17:09:39 +0100" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2009-12-21 16:04:23 +0000" MODIFIED_BY="[Empty name]">CINAHL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-09-06 17:09:39 +0100" MODIFIED_BY="[Empty name]">
<P>S1   MH "Craniomandibular disorders+"   </P>
<P>S2   MH "Myofascial Pain Syndromes+"   </P>
<P>S3   ((masticat* or myofasc* or orofacial*) and (pain* or dysfunction* or syndrom*))   </P>
<P>S4   (temporomandibular* or temporo-mandibular* or craniomandibular* or cranio-mandibular*)  </P>
<P>S5   (facial pain N3 psychogenic*) or (facial pain N3 atypical) and (facial pain N3 chronic)  </P>
<P>S6   (tmj* or cmd* or tmd* or 'facial arthromyalgia*')          </P>
<P>S7   (mpds not (myeloprolif* or myelo-prolif*))   </P>
<P>S8   S1 or S2 or S3 or S4 or S5 or S6 or S7   </P>
<P>S9   MH "analgesics+"</P>
<P>S10   (MH "Antiinflammatory Agents, Non-Steroidal)</P>
<P>S11   MH "steroids+"</P>
<P>S12   MH "central nervous system depressants+"  </P>
<P>S13   MH "muscle relaxants, central+"   </P>
<P>S14   MH "Antidepressive Agents+"  </P>
<P>S15   MH "Anticonvulsants+"</P>
<P>S16   MH "Capsaicin+"</P>
<P>S17   (acetaminophen* or paracetamol* or ibuprofen* or codeine* or morphine* or tramadol* or amantadine* or amitriptyline* or carbachol* or carbamazepine* or cimetidine* or 'dimethyl sulfoxide*' or interleukin-2 or quinine* or tetrahydrocannabinol* or buprenorphine* or enkaphalin* or fentanyl* or heroin or meperidine)  </P>
<P>S18   steroid*  </P>
<P>S19   (anaesthetic* or anesthetic* or baclofen* or diazepam*)   </P>
<P>S20   (sertraline* or bupropion* or citalopram* or fluoxetine* or fluvoxamine* or mianserin* or paroxetine* or sulpiride* or tryptophan* or amitriptyline* or clomipramine* or desipramine* or imipramine*)   </P>
<P>S21   (acetazolamide* or carbamazepine* or diazepam* or 'magnesium sulphate*' or melatonin* or phenobarbital* or phenytoin* or propofol* or thiopental* or valproic* or valproate* or vigabatrin*)   </P>
<P>S22   (aspirin* or curcumin* or dapsone* or diclofenac* or ibuprofen* or indomethacin* or ketoprofen* or mesalamine* or naproxen* or piroxicam* or salicylate* or sulfasalazine*)</P>
<P>S23   (painkillers* or pain-killer* or analgaes* or analges* or NSAID* or SSRI* or 'selective serotonin*' or rofecoxib* or celecoxib or meloxicam or muscle-relax* or doxepin or topical or amitriptyline* or antidepress* or anti-depress* or gabapentin* or meprobamate* or clonazepam* or lorazepam* or diazepam* or dothiepin* or paroxetine* or fluoxetine* or pharm*)</P>
<P>S24   S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 or S18 or S19 or S20 or S21 or S22 or S23</P>
<P>S25   S8 and S24  </P>
<SUBSECTION>
<HEADING LEVEL="3">Filter for CINAHL via EBSCO</HEADING>
<P>S1        MH Random Assignment or MH Single-blind Studies or MH Double-blind Studies or MH Triple-blind Studies or MH Crossover design or MH Factorial Design  </P>
<P>S2        TI ("multicentre study" or "multicenter study" or "multi-centre study" or "multi-center study") or AB ("multicentre study" or "multicenter study" or "multi-centre study" or "multi-center study") or SU ("multicentre study" or "multicenter study" or "multi-centre study" or "multi-center study")   </P>
<P>S3        TI random* or AB random*  </P>
<P>S4        AB "latin square" or TI "latin square" </P>
<P>S5        TI (crossover or cross-over) or AB (crossover or cross-over) or SU (crossover or cross-over)  </P>
<P>S6        MH Placebos  </P>
<P>S7        AB (singl* or doubl* or trebl* or tripl*) or TI (singl* or doubl* or trebl* or tripl*)</P>
<P>S8        TI blind* or AB mask* or AB blind* or TI mask*  </P>
<P>S9        S7 and S8</P>
<P>S10      TI Placebo* or AB Placebo* or SU Placebo*  </P>
<P>S11      MH Clinical Trials </P>
<P>S12      TI (Clinical AND Trial) or AB (Clinical AND Trial) or SU (Clinical AND Trial) </P>
<P>S13      S1 or S2 or S3 or S4 or S5 or S6 or S9 or S10 or S11 or S12  </P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>